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FIELD OF THE INVENTION 
This invention relates generally to multifunctional mag-
netic nanoparticle probes that may be used in both optical 
imaging and deep-tissue magnetic resonance imaging (MRI) 
and monitoring. More specifically, the present invention 
relates to magnetic nanoparticles that are coupled with 
ligand-based in vivo delivery, specific cell targeting, and a 
molecular probe approach for the detection of target nucleic 
acids or proteins associated with disease, infection, or injury. 
BACKGROUND OF THE INVENTION 
2 
are powerful tools for in vitro studies; however, they are not 
capable of quantifying gene expression in living cells. There 
is a clear need to develop molecular probes that can recognize 
target mRNA in living cells with high specificity and instan-
5 taneously convert such recognition into a measurable signal 
with a high signal-to-background ratio. 
With recent advances in functional genomics and proteom-
ics, there is an urgent need to develop technologies and strat-
egies to detect proteins, multi-protein complexes and protein-
10 protein interactions in vitro. For example, there is a lack of 
novel labeling reagents in performing in vivo protein expres-
sion and interaction studies. There exist few tools that can be 
used to visualize protein-protein interaction inside cells in 
deep tissue, and to track the interaction between drug mol-
15 ecules and the associated protein targets. There is virtually no 
existing method that enables studies of the dynamics of dif-
ferent intra-cellular molecular processes in deep tissue. This 
is a daunting challenge in that none of the many approaches 
under development to address these problems have yet dem-
20 onstrated compelling promise--even as generally effective 
laboratory-scale small animal models. 
Hair-pin oligonucleotide probes have enhanced specificity 
in detecting single-stranded RNA or DNA targets (Tsourkas 
et al, 2003). In particular, molecular beacons are a class of 
25 fluorescence-quenched hair-pin nucleic acid probes that can 
be used in a quantitative fashion; these probes fluoresce upon 
target recognition (i.e., hybridization) with potential signal 
enhancement of greater than 200 under ideal conditions. 
Structurally, they are dual-labeled oligonucleotides with a 
30 reporter fluorophore at one end and a dark quencher at the 
opposite end (Tyagi and Kramer; 1996). They are designed to 
have a target-specific probe sequence positioned centrally 
between two short self-complementary segments which, in 
the absence of target, anneal to form a stem-loop hairpin 
35 structure that brings the fluorophore in close proximity with 
the quencher. In this configuration the molecular beacon is in 
the "dark" state (Bernacchi and Mely, 2001). The hairpin 
opens upon hybridization with a complementary target, 
physically separating the fluorophore and quencher. In this 
Recent advances in nanotechnology and biology include 
the development of functional nanoparticles (electronic, opti-
cal, or magnetic) that are covalently linked to biological mol-
ecules such as peptides, proteins, and nucleic acids (See, e.g., 
Whaley et al., 2000; Bruchez et al., 1998; Chan et al., 1998; 
Mattoussi et al., 2000; Mitchell et al., 1999; Pathak et al., 
2001; Elghanianet al., 1997; Reynolds eta!., 2000; Mirkinet 
al., 1996; Storhoff et al., 1999; Alivisatos et al., 1996; 
Dubertet et al., 1996). Due to their size-dependent properties 
and dimensional similarities to biomolecules, these biocon- 45 
ju gates are well suited as contrast agents for in vivo magnetic 
resonance imaging (MRI)( Josephson et al., 1999; Bulte et al., 
1997; Bulte et al., 2001), as luminescent dyes for cellular 
imaging (Han et al, 2001; Nicewarner-Pena et al., 2001), and 
40 configuration the molecular beacon is in the "bright" state. 
Transition between dark and bright states allows for differen-
tiation between bound and unbound probes and transduces 
target recognition into a fluorescence signal (Matsuo, 1998; 
Liu et al., 2002). 
The unique target recognition and signal transduction 
capabilities of molecular beacons have led to their application 
in many biochemical and biological assays including quanti-
tative PCR (Vogelstein and Kinzler, 1999; Chen and Mul-
chandani, 2000), protein-DNA interactions (Fang et al., 2000; 
as molecular beacons for ultrasensitive optical imaging and 
detection (Tyagi and Kramer, 1996; Tyagi et al., 1998; Sokol 
et al., 1998). However, the great potential of magnetic nano-
particles and their bioconjugates as efficient, high throughput 
and versatile tools for in vivo targeting, sensing and tracking 
of nucleic acids and proteins has just begun to be exploited 
(Weissleider, 2001; Shen et al., 1993; Hagemann et al., 2000; 
Weissleider and Mahmood, 2001). 
The ability to monitor and quantify the level of gene 
expression in living cells in real time can provide important 
information concerning the production, temporal and spatial 
processing, localization, and transport of specific mRNA in 
different conditions. This new type of information could 
potentially revolutionize medical diagnostics and therapeu-
tics. Technologies currently available for analysis and quan-
tification of gene expression such as real-time RT-PCR, 
Northern blotting, expressed sequence tag (EST), serial 
analysis of gene expression (SAGE) and DNA microarrays 
50 Li et al., 2000), multiplex genetic analysis (Marras et al., 
1999; de Baar et al., 2001), and the detection of mRNA in 
living cells (Matsuo 1988; Sokol et al., 1998; Molenaar 
2001 ). However, false-positive signals due to protein-beacon 
interaction and nuclease-induced beacon degradation signifi-
55 cantly limit the sensitivity of the in vivo applications (Mitch-
ell, 2001). The thermodynamic and kinetic properties of 
molecular beacons are dependent on its structure and 
sequence in complex ways (Bonnet et al. 1999; Kuhn et al., 
2002). Moreover, the signal-to-background ratio in target 
60 detection is dependent not only on design (length and 
sequence of the stem and probe) but also on the quality of 
oligonucleotide synthesis and purification (Goddard et al., 
2000; Bonnet et al., 1998) and the assay conditions employed. 
Although molecular beacons, with the dual FRET (fluores-
65 cence resonance energy transfer) design (Tsourkas et al, 
2003a) and backbone modifications (Tsourkas at el, 2002b), 
can be used for sensitive and quantitative detection of mRNA 
US 7,459,145 B2 
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in living cells, they are optical-based probes and therefore 
cannot be used for deep tissue imaging of RNA expression 
due to light absorption and scattering. 
Compared with micrometer sized magnetic particles and 
chelates of paramagnetic ions such as gadolinium diethylen-
etriaminopentaacetic acid (Gd-DTPA), magnetic nanopar-
ticles are much more efficient as relaxation promoters and 
their effect on the relaxivities of water is measurable even at 
nanomolar concentrations, as demonstrated theoretically 
(Koenig and Kellar, 1995) and experimentally (Bulte et al, 10 
1992; Le Due et al, 2001; Josephson, Perez and Weissleder, 
2001; Perez et al, 2002). Specifically, the use of ferromag-
netic and superparamagnetic nanoparticles as contrast agents 
can induce a more than 10 fold increase in proton relaxivities 
(Coroiu et al, 1999). Based on the enzyme-cleavable contrast 15 
agents reported by Meade and coworkers (Huber et al, 1998; 
Louie et al, 2000), magnetic relaxation by gadolinium atoms 
is a short-range effect. The presence of a carbohydrate cap 
(less than 1 nm thick) prevents water molecules from contact-
ing the contrast agent Gd (HP-D03A). In contrast, superpara- 20 
magnetic nanoparticles (2-5 nm core size) are often coated by 
4 
stability, silica-based coatings are often supplemented with 
polymers such as polyethylene glycol (Butterworth et al., 
2001 ). In addition to post-synthesis approaches, some in situ 
coating approaches have been developed, such as the com-
monly used dextran coatings for MIONs (Kim et al., 2003). 
These coating processes also lead to multilayer coatings, 
which can result in a heterogeneous sample. In situ synthesis 
conditions limit the amount of functionalization that can be 
achieved. 
Recent research has identified several small regions ( 10-16 
amino acids) of proteins called protein transduction domains 
(PTDs) that possess the ability to traverse biological mem-
branes efficiently in a process termed protein transduction 
(Lewin et al., 2000; Wadia et al., 2002; Becker-Hapak et al., 
2001). Examples of PTDs are HIV-1 Tat, HSY VP22, and 
ANTP. It was shown that transduction occurs in a receptor-
and transporter-independent fashion that appears to target the 
lipid bilayer directly. Thus, in principle and practice, all cell 
types appear transducible. Proteins and compounds that are 
covalently linked to PTDs have proven to be useful in answer-
ing specific biological questions where other methods fail. 
Moreover, PTD fusion proteins have now been introduced 
into mice and exhibit delivery of active enzyme to all tissues, 
including across the blood-brain barrier. Recent research 
a thick dextran layer (10-20 nm) (Josephson, Perez and 
Weissleder, 2001), and the encapsulated nanoparticles are 
highly efficient contrast agents, yielding considerably stron-
ger effects than gadolinium compounds. 25 shows that magnetic particles as large as 40 nm and liposomes 
as large as 100 nm can be delivered into cells and tissues. Superparamagnetic iron oxide nanoparticles have been 
extensively studied for different applications including high-
density magnetic storage, magnetic nanostructures, catalytic 
and separation processes (Dyal et al., 2003), contrast agents 
for magnetic resonance imaging applications (Zhao et al., 30 
2002), functional cell labeling for in vivo tracking of stem 
cells and tumor progression (Lewin et al., 2000; Bulte et al., 
2001 ), cell and DNA sorting applications (Dressman et al., 
2003), drug delivery applications (Lanza et al.), and cellular 
mechanics studies. Most of these applications require water- 35 
soluble, stable, monodispersed, and uniformly sized mag-
netic nanoparticles. In addition, there is growing interest in 
applications of magnetic nanoparticles for intracellular 
molecular imaging. What is needed in the art is to have 
biocompatible magnetic nanoparticles with a size compa- 40 
rable to the molecular targets (approximately 2-15 nm), with 
multifunctional ligands. These ligands need to facilitate effi-
cient delivery of nanoparticles, enable specific cell-type rec-
ognition, provide suitable biological molecules (antibodies, 
oligonucleotides etc.) for intracellular targeting, and generate 45 
specific MRI contrast via clustering of magnetic nanopar-
ticles or other molecular switch mechanisms. 
A variety of coating strategies done both in situ and post-
synthesis have been developed for stabilization of magnetic 
nanoparticles. Post-synthesis coating processes include 50 
monolayer ligands (Liu and Xu, 1995; Yee et al., 1999), 
polymer coatings (Burke et al., 2002; Harris et al., 2003), and 
silica coatings (Butterworth et al., 2001; Santra et al., 2001; 
Lu et al., 2002). The monolayer ligand coatings rely on inter-
actions of chemical groups from both the ligand and nano- 55 
particle for effective adsorption or chemisorption of the 
ligand on the surface. These coatings tend to have limited 
colloidal stability due to weak steric hindrance in preventing 
aggregation and have limited opportunity for functionaliza-
tion. Residual surfactant on the surface of nanoparticles can 60 
result in inefficient or incomplete coatings with this approach. 
The amphiphilic polymer-based or silica-based coating 
approach often results in multilayer coatings (Lu et al., 2002), 
making the coating process difficult to control and resulting in 
a heterogeneous sample, and sometimes in the encapsulation 65 
of dimers or trimers of nanoparticles in the same shell (Lu et 
al., 2002). To improve ease offunctionalization and colloidal 
Traditionally, MRI subjects a tissue to a uniform magnetic 
field to analyze whether certain features are present or atypi-
cal in the subject. MRI uses changes in the angular momen-
tum or "spin" of atomic nuclei of certain elements to show 
locations of those elements within matter. In particular, a 
static magnetic field (typically between 0.2 and 4 Tesla) acts 
on the nuclei of atoms with fractional spin quantum numbers 
and polarizes them into alignment within the magnetic field. 
During MRI measurements, radio-frequency pulses of a 
given resonance energy are applied that flip the nuclear spins 
and disturb the orientation distribution. The radio-frequency 
(RF) pulses are in the form of a second, oscillating, RF mag-
netic field having a particular frequency referred to in the art 
as a resonant or Larmor frequency. This frequency is equal to 
the rate that the spins rotate or precess. When the magnetic 
field is turned off, the nuclei return (relax) to the initial state 
in a time dependent exponential fashion, thus giving signals 
which are electronically processed into recordable data. 
When the signals are spatially differentiated and of sufficient 
level, the data can be organized and displayed, allowing direct 
visualization of tissues and organs of a patient. Contrast 
agents, such as free metal ions, chelates, or insoluble metal 
compounds have been described for use in enhancing intrin-
sic contrast in MR imaging. Such metals may include, for 
example, iron, cobalt, zinc, cadmium, chromium, copper, 
nickel, manganese, and gadolinium. Magnetic nanoparticles 
induce a measurable change in the relaxation times T 1 and T 2 
(and T 2 *) of surrounding water molecules that can be visual-
ized using MRI. In addition, the coupling or clustering of 
magnetic nanoparticles generates a different effect on water. 
These effects of individual or clustered magnetic nanopar-
ticles on water can be differentiated using MRI. However, 
traditional MRI contrast agents, as well as the use of magnetic 
nanoparticles with MRI to target cell surface receptors, are 
not suitable for detecting differential levels of gene expres-
sion inside living cells. 
Therefore, there is a strong need in the art to provide 
multifunctional magnetic nanoparticle probes that are suit-
able for in vivo delivery and that have both signal transduction 
and target recognition properties. There is also a need for such 
compositions and methods that can be used for detection of 
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genetic transcription in vivo and in specific cell types Fur-
thermore, there is a need for such compositions and methods 
that can be used for both optical intra-cellular imaging and 
deep-tissue molecular imaging using MRI. Moreover, there is 
a need for such compositions and methods for the rapid and 
ultrasensitive in vivo detection of diseased cells; virus infec-
tion; the rapid detection of internal injury such as traumatic 
brain injury; and molecular imaging and monitoring of drug 
activities and therapeutic effects. 
SUMMARY OF THE INVENTION 
The present invention fulfills in part the need to develop 
multifunctional magnetic nanoparticle probes for intracellu-
lar molecular imaging and monitoring. The novel nanoprobe 
design and probe/target recognition and binding strategies 
provide high specificity and sensitivity, and enhanced signal-
to-noise ratio in molecular imaging. The peptide-based intra-
cellular delivery of probes and specific cell-type targeting 
provide the vehicle for efficient internalization of the mag-
netic nanoparticle probes into selected cells and organs. In 
addition, the nanoparticle probes of the present invention 
provide the capability of combining MRI and FRET-based 
optical imaging, providing for improved spatial resolution 
and versatility. These innovations and their integration will 
provide a platform for a new generation ofbiomagnetic con-
trast agents for deep tissue molecular imaging and monitor-
ing. The multifunctional magnetic nanoprobes offer a novel 
transduction mechanism for the in vivo detection of molecu-
lar markers for disease, infection, and injury. 
Accordingly, the present invention provides improved 
compositions and methods of use for more sensitive, specific, 
or rapid nucleic acid or polypeptide detection. 
The present invention also provides improved methods for 
the detection of gene expression associated with a response to 
external stimuli, e.g. a therapeutic drug candidate. The 
present invention further provides improved methods for the 
detection of gene expression, including genetic expression 
associated with an infection or disease state. 
The present invention also provides for the use of such 
compositions and methods in vivo. 
The present invention provides nanoparticle probe compo-
sitions for facilitating molecular imaging, comprising: a 
nucleic acid or polypeptide probe, a delivery ligand, and a 
detectable moiety, wherein the detectable moiety comprises a 
magnetic nanoparticle having a biocompatible coating 
thereon. The present invention also provides that the delivery 
ligand is a ligand that is capable of facilitating the traverse of 
a cell membrane. In a preferred embodiment, the magnetic 
nanoparticle is monocrystalline iron oxide nanoparticle 
(MION). The present invention also provides that the nano-
particle probe compositions may further comprise a second 
ligand that is capable of interacting with a molecule located 
on the outer surface of a particular type of cell or tissue. 
The present invention further provides compositions for 
facilitating signal transduction in molecular imaging, com-
prising two magnetic nanoparticle probe compositions. The 
first magnetic nanoparticle probe composition of the present 
invention comprises a first nucleic acid probe or protein 
probe, a delivery ligand, and a detectable moiety, wherein the 
detectable moiety comprises a magnetic nanoparticle having 
a biocompatible coating thereon. The second magnetic nano-
particle probe composition of the present invention comprises 
a second nucleic acid probe or protein probe, a delivery 
ligand, and a detectable moiety, wherein the detectable moi-
ety comprises a magnetic nanoparticle having a biocompat-
ible coating thereon. In certain embodiments, the first and the 
6 
second magnetic nanoparticleprobe compositions comprise a 
first nucleic acid probe and a second nucleic acid probe, 
respectively. 
The present invention provides that the first nucleic acid 
probe hybridizes to a first nucleic acid target sequence on a 
subject nucleic acid; the second nucleic acid probe hybridizes 
with a second nucleic acid target sequence on the same sub-
ject nucleic acid; and the first nucleic acid target sequence and 
the second nucleic acid target sequence are separated by a 
10 number of nucleotides on the subject nucleic acid such that 
the effect on water relaxation (i.e. a change in the value forT 1 , 
T 2 , or both) from interaction of the first and second magnetic 
nanoparticles can be detected to determine hybridization of 
both the first and the second nucleic acid probes. The inven-
15 tion further provides that first magnetic nanoparticle probe, 
the second magnetic nanoparticle probe, or both further com-
prise a resonance energy transfer moiety. 
In certain other embodiments, the invention provides com-
positions for facilitating signal transduction in molecular 
20 imaging, comprising two magnetic nanoparticle probe com-
positions wherein the first and the second magnetic nanopar-
ticle probe compositions comprise a first polypeptide probe 
and a second polypeptide probe, respectively. The present 
invention provides that such a composition is useful to facili-
25 tate the measurement of polypeptide expression, protein 
interactions, and protein clustering in both in vivo and in vitro 
systems using magnetic imaging/magnetic spectroscopic 
measurements. In a preferred embodiment, the present inven-
tion provides that the first and the second polypeptide probes 
30 bind to a first and a second target sequence on a single subject 
polypeptide. In another preferred embodiment, the present 
invention provides that the first polypeptide probe binds to a 
first subject polypeptide; the second polypeptide probe binds 
to a second subject polypeptide. When the first subject 
35 polypeptide interacts with the second subject polypeptide, the 
first and second magnetic nanoparticles are brought in close 
proximity (e.g. 2-50 nm), and the effect on water relaxation 
(change in T 1 , T 2 , or its combination for contrast detection) 
from interaction of the first and second magnetic nanopar-
40 ti cl es can be detected to determine binding of both the first 
and the second polypeptide probes. 
The present invention also provides methods for determin-
ing the expression of a subject nucleic acid, comprising intro-
ducing the magnetic nanoparticle probe composition of the 
45 present invention to a sample suspected of containing the 
subject nucleic acid; and detecting the presence of the subject 
nucleic acid by molecular imaging. The present invention 
provides the detection of the presence of the subject nucleic 
acid is measured by magnetic resonance imaging (MRI), or 
50 the detection may be determined by optical imaging, measur-
ing resonance energy transfer signals. 
The present invention also provides methods for determin-
ing the expression of a subject polypeptide or interaction of 
two polypeptides, comprising introducing the magnetic 
55 nanoparticle probe composition of the present invention to a 
sample suspected of containing the subject polypeptide(s); 
and detecting the presence of the subject polypeptide(s) by 
molecular imaging. The present invention provides the detec-
tion of the presence of the subject polypeptide is measured by 
60 magnetic resonance imaging (MRI), or the detection may be 
determined by optical imaging, measuring resonance energy 
transfer signals. 
The present invention provides novel approaches to engi-
neer biocompatible surface coatings for magnetic nanopar-
65 ticles using amphiphilic polymers. The biocompatible sur-
face coating of the present invention comprises discrete 
amphiphilic polymers that can be engineered to control the 
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thickness of the coating and to conjugate multiple ligands on 
the surface of the coating. These amphiphilic polymer mol-
ecules can be engineered either by self-assembled structure or 
8 
probe-target hybridization induces an altered effect on water 
relaxation compared with dispersed nanoparticles, leading to 
a contrast in MR imaging. 
by chelating metal particles in combination with polymers or 
polymerization, to create the coating for magnetic nanopar-
ticles. This approach can be used to combine different ligand 
conjugation approaches (for example, proteins, antibodies, 
peptides, nucleic acid probes, fluorescent dyes and other 
small molecules). This surface coating may be modified using 
bifunctional chelating agents or ligands to allow for multiple 10 
imaging modalities (e.g. MRI and optical imaging), or it may 
FIG. 2B shows the binding of two magnetic nanoparticle 
probe compositions to a first and second target sequence on a 
first and second subject proteins, respectively. The interaction 
of the first and second subject proteins results in the clustering 
of the two magnetic nanoparticles, which induces an altered 
effect on water relaxation compared with dispersed nanopar-
ticles, leading to a contrast in MR imaging. 
FIG. 2C shows the strategy of using multiple magnetic 
nanoparticle probe pairs, wherein the nucleic acid probes of 
each nanoparticle probe bind to the same target mRNA, to 
increase the signal-to-noise ratio. 
be used in combination with drug delivery and imaging appli-
cations, wherein drug molecules may either be encapsulated 
in the coated structure or conjugated to the polymer backbone 
of the coating material, or conjugated directly to the surface of 15 
the nanoparticle, or conjugated using multifunctional ligands 
FIG. 3 is transmission electron microscopy image of iron 
oxide (Fe3 0 4 ) particles with an average size of 6.6 nm and 
size variation of 11 %. The image is courtesy of Dr. Charles 
O'Connor at the University of New Orleans. 
on the surface of the engineered coating. 
The invention further provides methods for producing a 
magnetic nanoparticle probe composition for facilitating 
molecular imaging, comprising combining a magnetic nano-
particle with a biocompatible coating; adding a ligand that is 
capable of facilitating the traverse of a cell membrane; and 
adding a nucleic acid probe or polypeptide probe. The inven-
tion also provides that the methods may comprise the further 
step of adding a second ligand that is capable of interacting 
with a molecule located on the outer surface of a particular 
type of cell or tissue. The invention further provides that these 
methods may further comprise the step of adding a resonance 
energy transfer moiety to the magnetic nanoparticle probe 
composition. 
These and other objects, features, and advantages of the 
present invention will become apparent after a review of the 
following detailed description of the disclosed embodiments 
and the appended claims. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. lA is a schematic representation showing a single 
multifunctional magnetic nanoparticle probe consisting of a 
magnetic nanoparticle, a biocompatible coating, a delivery 
peptide, a second ligand for targeting, and an oligonucleotide 
hairpin probe complementary to a specific target nucleic acid 
sequence. 
FIG. lB is a schematic representation showing a single 
multifunctional magnetic nanoparticle probe consisting of a 
magnetic nanoparticle, a biocompatible coating, a delivery 
peptide, a second ligand for targeting, and an antibody spe-
cific for a target polypeptide. 
FIG. 4 is a schematic representation of the micellization 
20 procedure. 
FIG. 5 is a histogram showing the results of dynamic light 
scattering (DLS), used to determine the size of the micelle-
encapsulated magnetic iron oxide nanoparticle (MION) 
25 
probes. 
FIG. 6A is a graph showing the predicted proton relaxivity 
as a function of the magnetic field strength for magnetic 
nanoparticles with different sizes (adapted from Koenig & 
Kellar, 1995, Magn. Reson. Med. 34:227-233). FIG. 6B is a 
30 schematic representation showing that when two multifunc-
tional magnetic nanoprobes bind to a single target sequence, 
the magnetic nanoparticles are in close proximity. Due to 
direct interactions, the two magnetic nanoparticles should 
behave as a single, large nanoparticle. 
35 FIG. 7A is a schematic representation of the Fluorescence 
Resonance Energy Transfer (FRET) assay used to determine 
the effect of clustering of magnetic nanoparticles. In this 
embodiment, two MION probes comprise complementary 
oligonucleotides. The MION probes further comprise a 
40 FRET dye (Cy5 for one of the oligonucleotides, and Cy3 for 
the complementary oligonucleotide). The energy transfer 
from the donor (Cy3-MION) to the acceptor (Cy5-MION) is 
detected upon hybridization of the two oligonucleotides. FIG. 
7B shows a strategy to combine optical and MRI imaging of 
45 molecular markers in vivo. Donor and acceptor fluorescent 
dyes conjugated to a pair of magnetic nanoprobes results in a 
FRET signal when both are bound to the same target mRNA. 
FIG. SA-SD show graphs of the results of optical detection 
using FRET for the A) Cy3-oligonucleotide-micelle-MION 
50 probe+Cy5-oligonucleotide-micelle-MION probe combina-
tion, B) Cy3-oligonucleotide-micelle-MION probe alone, C) 
Cy5-oligonucleotide-micelle-MION probe alone, and D) a 
blank sample. Samples were excited at 500 nm to eliminate 
any significant direct excitation of the Cy5 dye. 
FIG. lC shows schematically a specific probe composition 
and in vivo delivery approach in which two or more magnetic 
nanoparticle probes are wrapped into a vesicle for delivery 
into deep tissue. In this case, the delivery ligand and second 
ligand for targeting are conjugated on the vesicle surface 
instead of on the nanoparticle coating surface. 55 FIG. 9 is a graph showing the T 2 relaxivity of the samples 
as a function of the MION (Fe) concentration. The diamonds 
represent bare particles, and the line connecting the diamonds 
represents a calibration curve for the particles. The square and 
the circle represent the Cy3-MI ON pro be and the Cy5-MI ON 
FIG. lD is a schematic representation showing one 
embodiment of the biocompatible coating of magnetic nano-
particle probe, consisting ofthephospholipid-linked polyeth-
ylene glycol (PEG). 
FIG. 2 shows the signal transduction mechanisms. 
60 probe, respectively. The square with the star represents the 
predicted value for the combination of the Cy3-MION probe 
and the Cy5-MION probe. The triangle represents the actual 
value, which is decreased, indicating an effect of interaction 
FIG. 2A shows the binding of two magnetic nanoparticle 
probe compositions to a subject nucleic acid (i.e. mRNA in 
this example) via the hybridization of the first and second 
nucleic acid probes to the complementary first and second 65 
target nucleic acid sequence on the subject mRNA molecule. 
The clustering of the two magnetic nanoparticles as a result of 
of the two MION probes. 
FIG. 10 is a schematic representation of the procedure for 
the simultaneous fluorescent labeling of and bioconjugation 
of the magnetic nanoparticles. 
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FIG. 11 shows results of magnetic resonance imaging of 
MDBK cells. 
FIG. llA is a graph showing the T2 relaxation times (in 
ins) of 500 ml cell suspension samples. Column 1 shows 
values for MDBK cells with MIONs, and Column 2 shows 
values for the control of MDBK cells alone. 
FIG. llB shows an image of a cross-section of samples 
from a 3 T Siemens MRI system. The first and fourth samples 
are control samples of media only; the second sample is a 
control of MDBK cells with media; and the third sample is 
MdDBK cells with MIONs and media. 
FIG. 12 is a schematic illustration of three different conju-
gation schemes for linking the delivery peptide to nucleic acid 
pro bes. (A) The streptavidin-biotin linkage in which a nucleic 
acid probe is modified by introducing a biotin-dT to the 
quencher arm of the stem through a carbon-12 spacer. The 
biotin-modified peptides are linked to the modified nucleic 
acid probe through a streptavidin molecule, which has four 
biotin-binding sites. (B) The thiol-maleimide linkage in 
which the quencher-arm of the nucleic acid probe stem is 
modified by adding a thiol group which can react with a 
maleimide group placed to the C terminus of the peptide to 
form a direct, stable linkage. (C) The cleavable disulfide 
bridge in which the peptide is modified by adding a cysteine 
residue at the C terminus which forms a disulfide bridge with 
the thiol-modified nucleic acid probe. This disulfide bridge 
design allows the peptide to be cleaved from the nucleic acid 
probe by the reducing environment of the cytoplasm. 
FIG. 13 shows the detection of Survivin mRNA in live 
HDF and MiaPaca-2 cells. (A) Strong fluorescence signal 
was observed in MiaPaca-2 cells after 60 min of incubation 
with peptide-linked nucleic acid probes. Note that essentially 
all cells shown fluorescence. (B) Survivin mRNA molecules 
in MiaPaca-2 cells seemed to be concentrated near one side of 
the cell nucleus HDF cells. (C) Only very low fluorescence 
signal can be observed in HDF cells, but with a survivin 
mRNA localization pattern. 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention may be understood more readily by 
reference to the following detailed description of the pre-
ferred embodiments of the invention and the Examples 
included therein. Before the present compounds, composi-
tions, and methods are disclosed and described, it is to be 
understood that this invention is not limited to any specific 
nucleic acid probes, specific nucleic acid targets, specific 
protein or polypeptide probes, specific polypeptide targets, 
specific cell types, specific conditions, or specific methods, 
etc., as such may, of course, vary, and the numerous modifi-
cations and variations therein will be apparent to those skilled 
in the art. It is also to be understood that the terminology used 
herein is for the purpose of describing particular embodi-
ments only and is not intended to be limiting. As used in the 
specification and in the claims, "a" or "an" can mean one or 
more, depending upon the context in which it is used. Thus, 
for example, reference to "a nucleic acid probe" can mean that 
one or more than one nucleic acid probe can be utilized. 
In accordance with the purpose(s) of this invention, as 
embodied and broadly described herein, the present invention 
provides, in one aspect, nanoparticle probe compositions for 
facilitating intracellular molecular imaging, comprising: a 
targeting probe, a delivery ligand, and a detectable moiety, 
wherein the detectable moiety comprises a magnetic nano-
particle having a biocompatible coating thereon (FIGS. lA 
and lB) In certain embodiments, the composition further 
10 
comprises a targeting ligand that is capable ofinteracting with 
a molecule on a particular type of cell or tissue. 
In certain embodiments of the present invention, the mag-
netic nanoparticle comprises a metal selected from the group 
consisting of selected from the group consisting of iron, 
cobalt, zinc, cadmium, nickel, gadolinium, chromium, cop-
per, manganese, and their oxides. In other embodiments, the 
magnetic nanoparticle is an alloy with a metal selected from 
the group consisting of gold, silver, platinum, and copper. The 
10 invention further provides that the magnetic nanoparticle may 
comprise a free metal ion, a metal oxide, a chelate, or an 
insoluble metal compound. In certain embodiments, the mag-
netic nanoparticle is selected from the group consisting of 
Fe304, Fe204, FexPty, CoxPty, MnFexOy, CoFexOy, 
15 NiFexOy, CuFexOy, ZnFexOy, and CdFexOy, wherein x and 
y vary depending on the method of synthesis. In other 
embodiments, the magnetic nanoparticle further comprises a 
metal coating selected from the group consisting of gold, 
silver, iron, cobalt, zinc, cadmium, nickel, gadolinium, chro-
20 mium, copper, and manganese, and an alloy thereof. In yet 
other embodiments, the magnetic nanoparticle comprises ter-
bium or europium. In certain preferred embodiments, the 
magnetic nanoparticle is selected from the group consisting 
ofmonocrystalline iron oxide nanoparticle (MION), chelate 
25 of gadolinium, and superparamagnetic iron oxide (SPIO). In 
a preferred embodiment, the magnetic nanoparticle is monoc-
rystalline iron oxide nanoparticle (MION). 
In certain preferred embodiments of the present invention, 
the biocompatible coating is selected from the group consist-
30 ing of dextran, dendrimers, amphiphilic polymers/bio-poly-
mers (e.g. phospholipids and peptides), polymers, surfactants 
or chemical compounds with chelating properties for mag-
netic nanoparticles or high affinity adsorption (e.g. both 
chemisorption or physical adsorption) on the surface of mag-
35 netic nanoparticles, silicon oxide, silica, silica-PEG, meso-
porous structures (silica or polymers or their combinations) 
for encapsulation of nanoparticles, or any other preferred 
combination of the above. In a further preferred embodiment, 
the biocompatible coating is an amphiphilic polymer. In an 
40 even further preferred embodiment, the biocompatible 
amphiphilic polymer coating is a phospholipid-PEG coating. 
In other preferred embodiments phospholipid-PEG may be 
modified with various bioconjugation reactive groups, 
including, but not limited to amines, maleimide, thiols, car-
45 boxylic acids, NHS esters, and the derivatives of these reac-
tive groups to form phospholipid-PEG-X (wherein Xis the 
modified bioconjugation group(s)). In a further preferred 
embodiment, mixture of modified phospholipid-PEG mol-
ecules with different bioconjugation compatible groups may 
50 be used for the coating process. Dextran-coated iron oxide 
nanoparticles have been approved for clinical human use by 
the FDA. Extensive studies on the biosafety, biodistribution, 
and metabolism of these superparamagnetic particles have 
shown that they are biocompatible and are degraded inside 
55 the body. The iron oxide is recycled and becomes raw mate-
rials for blood synthesis (hemoglobin). The peptides attached 
to the particle surface could elicit an immune response if the 
particles are used in vivo for a long period. However, this is 
not expected to be a problem when the particles are only used 
60 for short-term diagnostics purposes. This problem can be 
further mitigated by coating the particles with derivatives of 
polyethylene glycols (PEG), which are known to shield pro-
teins from binding to antibodies. 
In certain other preferred embodiments, the coating mate-
65 rials self assemble to form the biocompatible coating. As used 
herein, a "coating material" refers to a dextran molecule, a 
dendrimer, an amphiphilic polymer/bio-polymer (e.g. phos-
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pholipid, peptide etc.), a polymer, a surfactant, or chemical 
compound with chelating properties for a magnetic nanopar-
ticle or high affinity for adsorption on a magnetic nanopar-
ticle. In further preferred embodiments, these self-assembled 
coating materials form a micelle, liposome, or dendrimer 
shaped structure. In a further preferred embodiment, the coat-
ing materials form only a monolayer on the surface of mag-
netic nanoparticle. In a further preferred embodiment, the 
monolayer thickness can be engineered by controlling the 
chain length of the self assembled structure (e.g. the PEG 10 
chain length may be controlled for a phosoholipid-PEG bio-
compatible coating). The present invention also provides that 
the biocompatible coating can be formed by cross-linking or 
polymerization of raw coating materials to form a network of 
molecules on the surface of the magnetic nanoparticle. In a 15 
further preferred embodiment, the crosslinking or polymer-
ization process can be controlled by altering the time of the 
reactions, the amount of raw coating material, the polymer 
chain length, the temperature, and other processing condi-
tions. 20 
In certain preferred embodiments, the surface of the bio-
compatibly coated magnetic nanoparticles of the present 
invention comprise a delivery ligand. As used herein, a "deliv-
ery ligand" refers to a molecule that is capable of effectively 
delivering the magnetic nanoparticle probe across a cell 25 
membrane or across both a cell membrane and additional 
intracellular organelle membrane. In a further preferred 
embodiment for intracellular delivery, the delivery ligand 
selected allows for either endocytic or non-endocytic uptake 
pathways. In a more preferred embodiment, the magnetic 30 
nanoparticle probe is delivered using a non-endocytic uptake 
pathway, using a delivery ligand selected from the group 
consisting of a protein transduction domain peptide (PTD) 
and a cell penetrating peptide (CPP). In a further preferred 
embodiment, the delivery ligand is a TAT peptide. In other 35 
embodiments, the delivery ligand may be selected from a 
group consisting of HIV-1 TAT, HSY VP22, ANTP, poly-
Arginine, and Arginine-rich peptides such as W/R, NLS*, 
AlkCWK18, DiCWK18, transportan, DipaLytic, K16RGD, 
Pl, P2, P3, P3a, P9.3, Plae, Kplae, cKplae, MGP, HA2, 40 
LARL46, Hel-11-7, KK, KWK, RWR, and Loligomer. The 
specific sequences of certain delivery peptides are disclosed 
in Schwartz and Zhang (2000), and are as follows: 
45 
(SEQ ID NO, 1) 
TAT (with amino acid sequence YGRKKRRQRRR) 
(SEQ ID NO, 2) 
HSV VP22 DAATATRGRSAASRPTERPRAPARSASRPRRPVE 
50 
(SEQ ID NO, 3) 
ANTP (RQIKIWFQNRRMKWKK) 
(SEQ ID NO, 4) 
W/R (RRWRRWWRRWWRRWRR) 
55 (SEQ ID NO, 5) 
NLS ( TPPKKKRKVEDP) 
(SEQ ID NO, 6) 
AlkCWKis ( CWKKKKKKKKKKKKKKKKKK) 
(SEQ ID NO, 7) 60 
(SEQ ID NO, 8) 
Transportan (GWTLNSAGYLLGKINLKALAALAKKIL) 
(SEQ ID NO, 9) 65 
DipaLytic (GLFEALEELWEAK) 
12 
-continued 
(SEQ ID NO, 10) 
(SEQ ID NO, 11) 
Pl (Ki 6 GGCMFGCGG) 
(SEQ ID NO, 12) 
P2 (Ki 6 ICRRARGDNPDDRCT) 
(SEQ ID NO, 13) 
P3 (KKWKMRRNQFWVKVQRbAK(B)bA) 
(SEQ ID NO, 14) 
P3a (VAYISRGGVSTYYSDTVKGRFTRQKYNKRA) 
(SEQ ID NO, 15) 
P9.3 (IGRIDPANGKTKYAPKFQDKATRSNYYGNSPS) 
(SEQ ID NO, 16) 
Plae (PLAEIDGIELTY) 
(SEQ ID NO, 1 7) 
Kplae (Ki 6 GGPLAEIDGIELGA) 
(SEQ ID NO, 18) 
cKplae (Ki 6 GGPLAEIDGIELCA) 
(SEQ ID NO, 19) 
MGP (GALFLGFLGGAAGSTMGAWSQPKSKRKV) 
(SEQ ID NO, 20) 
HA2 (WEAK(LAKA) 2 LAKH(LAKA) 2 LKAC) 
(SEQ ID NO, 21) 
(SEQ ID NO, 22) 
Hel-11-7 (KLLKLLLKLWLKLLKLLL) 
(SEQ ID NO, 23) 
KK ( (KKKK) 2 GGC) 
(SEQ ID NO, 24) 
KWK ( (KWKK) 2 GCC) 
(SEQ ID NO, 25) 
RWR ( (RWRR) 2 GGC) 
(SEQ ID NO, 26) 
Loligomer ((K9K2) (K4) (K8)GGKKKKK-NLS). 
wherein NLS consists of the NLS sequence 
disclosed in this paragraph as SEQ ID N0,5. 
In certain other embodiments, the magnetic nanoparticle 
probe may be delivered using endocytic routes. In a further 
preferred embodiment, the endocytic route may require a 
ligand which has both targeting and delivery functions e.g. 
folic acid for targeting folic acid receptors on cancer cells. In 
certain other preferred embodiments, the endocytic route tar-
geted delivery may be supplemented with endosomal disrup-
tion agents or agents for early release of probes from endo-
somes such as pH sensitive polymeric materials or ligands 
selected from certain viruses. In certain other preferred 
embodiments, the probe may be delivered using a transfec-
tion agent, which may be lipid-, polymer-, dendrimer-based 
or their combinations, or their combinations with themselves 
or with other ligands such as peptides, proteins, and small 
molecules. 
In certain embodiments, the coated magnetic nanoparticles 
are further modified with a second ligand. The present inven-
tion provides that the second ligand is a molecule that is 
capable of interacting with a molecule on a particular type of 
cell or tissue. In a preferred embodiment, the second ligand is 
selected from a group consisting of a polypeptide, a peptide, 
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an antibody, an antibody fragment, an oligonucleotide-based 
aptamer with recognition pockets, and a small molecule that 
binds to a specific cell surface receptor or polypeptide on the 
outer surface of the cell wherein the cell surface receptor or 
polypeptide is specific to that cell type. The present invention 
provides that the second ligand has a function to target a 
specific tissue, cell type, or disease-specific marker. As used 
herein, the term "disease-specific marker" refers to the 
increased expression of certain proteins on the cell surface of 
a diseased cell; the expression of foreign protein (e.g. viral 
proteins) expressed on cell surface of the infected cell; and the 
expression of markers associated with specific pathophysi-
ological states such as angiogenesis, which may be associated 
with tumor tissue. In certain embodiments this targeting func-
tion may increase the efficiency of intracellular delivery. In a 
further preferred embodiment, the magnetic nanoparticles 
probe has ligands with both targeting and delivery functions. 
As used herein, the term "targeting function" refers to the 
ability of a molecule to specifically interact with a molecule 
on a particular type of tissue or cell, including a cancerous or 
diseased cell. As also used herein, the term "delivery func-
tion" refers to the ability of a molecule to effectively deliver 
the magnetic nanoparticle probe across a cell membrane or 
across both a cell membrane and an additional intracellular 
organelle membrane In one embodiment, the targeting and 
delivery function may be achieved by the use of a single 
ligand or by using two or more ligands attached to the bio-
compatible coating of the magnetic nanoparticle probe. In 
certain embodiments, the ligands may be removed from the 
magnetic nanoparticle probe after intracellular delivery of the 
probe. This removal process may be based, for example, on 
reduction, oxidation, light (including UV, visible, infrared) 
associated cleavage, proteolytic cleavage, and enzymatic 
reactions. 
In certain other preferred embodiment the ligand attached 
coated magnetic nanoparticles are further modified with 
reporter probe molecules for multi-modality imaging abilities 
such as fluorescent dyes, radioisotopes, luminescent mol-
ecules/bioluminescent polypeptides, or other biomolecules. 
In certain other embodiments, drug molecules may also be 
encapsulated, conjugated, or attached to the coating either on 
the surface or at its backbone to monitor the drug bioavail-
ability, delivery, and lifetime of the drug, along with the MRI 
and optical imaging applications. 
In a preferred embodiment central to this invention, the 
targeting probe comprises a nucleic acid probe attached to the 
surface of the coated magnetic nanoparticle. The attachment 
of the nucleic acid probe to the surface of the coated magnetic 
nanoparticle may involve a covalent attachment or high affin-
ity adsorption/binding using non-covalent attachment 
through other biomolecules such as peptides or proteins 
attached to the magnetic nanoparticle coating surface, for 
example, utilizing a streptavidin-biotin linkage. In one pre-
ferred embodiment, the nucleic acid probe is covalently 
attached to the surface of the probe through chemical modi-
fications to generate a functional group either at the 3' end, the 
5' end, or anywhere in the sequence of the probe (i.e. an 
internal modification of nucleic acid probe). In a further pre-
ferred embodiment, the coated magnetic nanoparticle probe 
comprising the nucleic acid probe is further modified with a 
ligand or ligands to effectively target and deliver the magnetic 
nanoparticle probe. In a further preferred embodiment the 
coated magnetic nanoparticle probe is also modified with a 
fluorescent reporter molecule, a radioisotope reporter mol-
ecule, or both. 
In a preferred embodiment, the nucleic acid probe selected 
for attachment to the magnetic nanoparticle probe is either 
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fully complementary or partially complementary to a target 
nucleic acid sequence on a subject nucleic acid. In a further 
preferred embodiment, two or more magnetic nanoparticle 
probes comprising a nucleic acid probe are used. The two or 
more target nucleic acid sequences are selected in a way such 
that when the two or more nucleic acid probes hybridize to the 
respective target nucleic acid sequence, the two or more mag-
netic particles are brought in close proximity (FIGS. 2A and 
2C). In a preferred embodiment the nucleic acid probes 
10 hybridizes to target sequence in a complementary fashion to 
form a duplex. In certain embodiments the nucleic acid 
probes may be designed to form triplexes or other secondary 
structures required based on mRNA sequence requirement to 
create contrast based on magnetic relaxation. In a further 
15 preferred embodiment, the distance between the two mag-
netic particles may be chosen based on the design of the target 
nucleic acid sequences, the nucleic acid probes, and the sec-
ondary/tertiary structure of the target nucleic acid sequences 
such that a significant shift in magnetic relaxation (Tl and/or 
20 T2 relaxation time) is achieved as compared to single mag-
netic nanoparticle probe hybridized to a target sequence. In 
certain embodiments, multiple pairs of magnetic particles 
with nucleic acid probes are used, as illustrated in FIG. 2C, 
wherein the nucleic acid probes of each of the magnetic 
25 nanoparticle probes hybridize with a single subject target 
nucleic acid to enhance the signal-to-noise ratio and to gen-
erate a significant MR contrast. 
In certain embodiments, the present invention further pro-
vides compositions for facilitating intracellular molecular 
30 imaging, comprising at least two magnetic nanoparticle 
probe compositions. The first magnetic nanoparticle probe 
composition of the present invention comprises a first target-
ing probe, a delivery ligand, and a detectable moiety, wherein 
the detectable moiety comprises a magnetic nanoparticle hav-
35 ing a biocompatible coating thereon. The second magnetic 
nanoparticle probe composition of the present invention com-
prises a second targeting probe and a detectable moiety, 
wherein the detectable moiety comprises a magnetic nano-
particle having a biocompatible coating thereon. In one 
40 embodiment, the first and second targeting probes are nucleic 
acid probes. The present invention provides that the first 
nucleic acid probe hybridizes to a first nucleic acid target 
sequence on a subject nucleic acid; the second nucleic acid 
probe hybridizes with a second nucleic acid target sequence 
45 on the subject nucleic acid; and the first nucleic acid target 
sequence and the second nucleic acid target sequence are 
separated by a number of nucleotides on the subject nucleic 
acid such that an effect on water relaxation from interaction 
between the first and second magnetic nanoparticles can be 
50 detected to determine hybridization of both the first and sec-
ond nucleic acid probes. 
In a preferred embodiment for cellular or in vivo molecular 
imaging, mRNA is the subject nucleic acid. In a further pre-
ferred embodiment, the subject mRNA has a characteristic 
55 up-regulation or down-regulation that is associated with a 
disease-specific or injury-specific condition; the subject 
mRNA is a foreign mRNA such as a viral or bacterial mRNA; 
or the subject mRNA is specific to a particular cell phenotype, 
stem cell lineage, or cell differentiation. In a preferred 
60 embodiment, the nucleic acid probe will form a hairpin struc-
ture, wherein the hairpin oligonucleotide probes have differ-
ent loop lengths and stem lengths, depending on the specific 
target mRNA and requirements of probe/target hybridization 
specificity, sensitivity, and signal-to-noise ratio. In a further 
65 preferred design the hairpin shape (length of stem and loop 
domain) of the nucleic acid probe may be designed based on 
thermodynamic, kinetic, and its combination principles to 
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increase specificity of the probe and reduce nonspecific inter-
actions of the nucleic acid probe nucleotides. In certain other 
embodiments, the nucleic acid probe may be chosen to have 
a linear or random structure. 
In one embodiment of the present invention, the first or 
second nucleic acid probes comprise 10 to 90 nucleotides. In 
16 
2'-0-methyl nucleotide. In certain embodiments, regular 
nucleic acid probes without any modification may be used to 
target the mRNA of interest. 
The present invention provides that the first nucleic acid 
probe, the second nucleic acid probe, or both may have a 
linear, randomly coiled, or stem-loop structure when not 
hybridized to the first or the second nucleic acid target 
sequence. In a preferred embodiment, the nucleic acid probes 
form a stem-loop structure when not hybridized to the respec-
a preferred embodiment, the first or second nucleic acid 
probes comprise 10 to 40 nucleotides. Even more preferred, 
the first or second nucleic acid probes comprise 15 to 30 
nucleotides. More preferred, the first or second nucleic acid 
probes comprise 20 to 25 nucleotides. 
10 tive target sequence. In another embodiment the first or sec-
ond magnetic nanoparticle probe further incorporates a reso-
nance energy transfer donor or acceptor moiety on the 
biocompatible coating, such that a resonance energy transfer 
signal from interaction between the donor moiety and the 
In various embodiments, the first nucleic acid target 
sequence and the second nucleic acid target sequence are 
separated by 10 to 150 nucleotides, or separated by 10, 20, 30, 
40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 nucle-
otides. As discussed below, the preferred number of separat-
ing nucleotides will vary depending upon the size of the 
nanoparticles and the size of the biocompatible coating, and 
can be routinely determined by one of skill in the art in view 20 
of the present disclosure. 
15 acceptor moiety on the first and second magnetic nanoparticle 
probes can be detected to determine the hybridization of the 
first and the second nucleic acid probes. In a preferred 
embodiment, the resonance energy transfer signal is due to 
fluorescence resonance energy transfer. 
In theory, the oligonucleotides on the nanoparticle surface 
could generate an antisense effect by hybridizing with mRNA 
molecules inside cells, but this effect should be minor because 
(a) the oligonucleotide probes we will use are very short 
(14-24 bases) and (b) the nanoprobes are only used for short-
In other preferred embodiments of the present invention, 
the chemistry of the nucleic acid probe(s) are chosen to be 
resistant to nuclease and proteolytic activity, with high affin-
ity for the target sequence with low affinity for nonspecific 
binding. For example, a nucleic acid probe of the present 
invention can be chemically synthesized using naturally 
occurring nucleotides or variously modified nucleotides 
designed to increase the biological stability of the molecules 
or to increase the physical stability of the duplex formed 
between the complimentary nucleic acids, e.g., phospho-
rothioate derivatives and acridine substituted nucleotides can 
25 term diagnosis of diseases (such as infection) and injuries. 
Specifically, as far as diagnosis is concerned, the binding 
between oligonucleotide probes and specific mRNAs in the 
diseased or injured cells should not have a large detrimental 
effect on the health of the patient. If the nanoprobes are being 
30 delivered into normal cells as well, the oligonucleotide may 
not have any effect provided there is no target mRNA inside 
the normal cell (such as mutations). The antisense effect of 
the magnetic nanoparticle probe could be used as a therapeu-
be used. Preferred examples of classes of modified nucle-
otides which can be used to generate the nucleic acid probes 35 
are a 2'-0-methyl nucleotide and a peptide nucleic acid back-
bone. Additional examples of modified nucleotides which can 
be used to generate the nucleic acid probes include, for 
example, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-io-
douracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(car- 40 
boxyhydroxylmethyl)uracil, 5-carboxymethylaminomethyl-
2-thiouridine, 5-carboxymethylaminomethyluracil, 
dihydrouracil, beta-D-galactosylqueosine, inosine, N6-iso-
pentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-
dimethylguanine, 2-methyladenine, 2-methylguanine, 3-me- 45 
thylcytosine, 5-methylcytosine, N6-adenine, 
tic or monitoring agent. 
In additional embodiments, the invention provides meth-
ods for detecting a subject nucleic acid, comprising combin-
ing the composition described herein with a sample suspected 
of containing a subject nucleic acid, and detecting hybridiza-
tion by differential MRI contrast to determine the presence or 
absence, and/or the expression level of the subject nucleic 
acid in the sample in vitro or in vivo. As used herein, the term 
"MRI contrast" refers to an effect on the water relaxation in a 
particular sample. In some preferred embodiments, the meth-
ods can be performed in vivo. Therefore, in a preferred 
embodiment of this method, the sample contains a living cell, 
a living animal, or a living human being. The invention pro-
vides that the methods may be performed with samples com-
prising living tissues and cells that are taken out of the body, 
or that remain in situ. 
The methods of the present invention further include detec-
tion of changes in the levels of expression of a nucleic acid 
target, or in RNA transcript, such that alterations of gene 
expression can be monitored as a result of the dose-dependent 
cellular response to external stimuli, such as drug molecules, 
7 -methy !guanine, 5-methy laminomethy !uracil, 5-meth-
oxyaminomethy l-2-thiouracil, beta-D-mannosylqueosine, 
5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-meth-
ylthio-N-6-isopentenyladenine, uracil-5-oxyacetic acid (v), 50 
wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-me-
thyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, 
uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid 
(v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypro-
pyl) uracil, (acp3)w, and 2,6-diaminopurine. 55 hormones, growth factors, temperature, shear flow, or micro-
gravity, for example. The invention further provides that the 
compositions can be used to visualize, i.e., through MRI, 
fluorescence, or luminescence, the location and relative 
amount of gene expression in tissues and cells. The invention 
In another embodiment, the nucleic acid probe of the 
present invention comprises at least one modified sugar moi-
ety selected from the group including but not limited to ara-
binose, 2-fluoroarabinose, xylulose, and hexose. In yet 
another embodiment, the nucleic acid probe of the present 
invention comprises at least one modified phosphate back-
bone selected from the group consisting of a phosphorothio-
ate, a phosphorodithioate, a phosphoramidothioate, a phos-
phoramidate, a phosphordiamidate, a methylphosphonate, an 
alkyl phosphotriester, and a formacetal or analog thereof. As 
stated above, a preferred example of a modified nucleotide 
which can be used to generate the nucleic acid probes is a 
60 also provides that the compositions can be used to permit the 
detection of a subject nucleic acid, indicating the presence of 
a virus, a diseased cell, or a traumatic injury. 
In diagnostic or prognostic detection methods, the subject 
nucleic acid can comprise a genetic point mutation, deletion, 
65 or insertion relative to a naturally occurring or control nucleic 
acid. Such screening methods can permit the detection of the 
subject nucleic acid indicating the presence of a genetically 
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associated disease, such as certain cancers, in the sample. 
There are many well-known examples of genetic mutations 
already in the art that are indicative of a disease state. The 
methods include the detection of nucleic acids comprising 
K-ras, survivin, p53, p16, DPC4, or BRCA2. Furthermore, 
the methods can be used to detect the amount of a subject 
nucleic acid being produced by an organism for purposes 
other than diagnosis or prognosis of a disease or condition. 
Resonance energy transfer detections of the present invention 
can be performed with the assistance of single- or multiple-
photon microscopy, time-resolved fluorescence microscopy 
or fluorescence endoscopy, as detailed below. 
One embodiment of the present invention provides mag-
netic nanoparticle probe compositions comprising nucleic 
acid probes, and methods that measure a resonance energy 
transfer, for example, a fluorescent signal due to FRET or 
LRET as a result of two different nucleic acid probes hybrid-
izing to the same target nucleic acid of interest. This approach 
utilizes a pair of magnetic nanoparticle probes with different 
nucleic acid probes that hybridize to a single subject nucleic 
acid. One magnetic nanoparticle probe further comprises a 
donor fluorophore on the surface ofits biocompatible coating, 
and the second magnetic nanoparticle probe comprises an 
acceptor fluorophore on the surface ofits biocompatible coat-
ing (FIG. 7B). Probe sequences are chosen such that the 
magnetic nanoparticle probes hybridize adjacent to each 
other on a single nucleic acid target in a way that their respec-
tive fluorophores have FRET or LRET. Emission from the 
acceptor fluorophore serves as a positive signal in the FRET/ 
LRET based optical detection assay. This will allow sensitive 
detection of a target nucleic acid inside cells in shallow tissue 
with higher spatial resolution (approximately 200 mm) as 
compared to the spatial resolution of MRI (approximately 0.1 
mm). 
The magnetic nanoparticle probes of the invention utilize 
the principle of resonance energy transfer between a donor 
moiety and an acceptor moiety. In a preferred embodiment, 
the resonance energy transfer is fluorescence resonance 
energy transfer (FRET), in which the first and second mag-
netic nanoparticle probes are labeled with donor and acceptor 
moieties on the surface of their biocompatible coatings, 
respectively, wherein the donor moiety is a fluorophore and 
the acceptor moiety may be a fluorophore, such that fluores-
cent energy emitted by the donor moiety is absorbed by the 
acceptor moiety when both probes are hybridized to the first 
and second target sequences respectively on the same nucleic 
acid subject. In one embodiment of the present invention, the 
acceptor moiety is a fluorophore that releases the energy 
absorbed from the donor at a different wavelength; the emis-
sions of the acceptor may then be measured to assess the 
progress of the hybridization reaction. 
In preferred embodiments, the resonance energy signals 
are due to fluorescence resonance energy transfer (FRET) or 
luminescence resonance energy transfer (LRET). In embodi-
ments wherein the resonance energy transfer signal is due to 
fluorescence resonance energy transfer, the donor moiety can 
18 
In other embodiments, the resonance energy transfer signal 
is due to luminescence resonance energy transfer (LRET) and 
the donor moiety is a lanthanide chelate. In some preferred 
embodiments where the resonance energy signal is due to 
LRET, the donor moiety can be Europium or Terbium. Fur-
thermore, in some embodiments where the resonance energy 
signal is due to LRET, the donor moiety can be a lanthanide 
chelate such as DTPA-cytosine, DTPA-cs124, BCPDA, 
BHHCT, Isocyanato-EDTA, Quantum Dye, or W1024 and 
10 the acceptor moiety can be Cy-3, ROX or Texas Red. In some 
embodiments, due to the range of effective resonance energy 
transfer of the lanthanide chelate, multiple acceptor moieties 
may be employed. The donor moiety can be a lanthanide 
chelate and the acceptor moiety can be a phycobiliprotein. In 
15 certain embodiments, the phycobiliprotein is Red Phyco-
erythrin (RPE), Blue Phycoerythrin (BPE), or Allophycocya-
nin (APC). Additional examples ofLRET donor and acceptor 
moieties useful in the present invention are provided below. 
Magnetic nanoparticle probes of the present invention may 
20 be labeled with donor and acceptor moieties on the biocom-
patible coating surface so that the resulting fluorescence or 
luminescence resonance energy transfer signal may be 
detected upon probe/target hybridization (FIG. 7B), in addi-
tion to the MRI signal. In a specific embodiment, the follow-
25 ing donor and acceptor pairs are used: a luminescent lan-
thanide chelate, e.g., terbium chelate or lanthanide chelate, is 
used as the donor, and an organic dye such as fluorescein, 
rhodamine or Cy5, is used as the acceptor. Preferably, terbium 
is used as a donor and fluorescein or rhodamine as an accep-
30 tor, or europium is used as a donor and Cy5 as an acceptor. 
In contrast to using two linear oligonucleotide probes 
attached to two different magnetic nanoparticles, nucleic acid 
probes with a stem-loop hairpin structure offer further reduc-
tion in background fluorescence as well as enhanced speci-
35 ficity, which is helpful particularly when detection of allelic 
variants or point mutations is desired (Bonnet et al., 1999; 
Tsourkas et al., 2002a). 
The nucleic acids of the present invention may be substan-
tially isolated or alternatively unpurified. An "isolated" or 
40 "purified" nucleic acid is one that is substantially separated 
from other nucleic acid molecules that are present in the 
natural source of the nucleic acid. Preferably, an "isolated" 
nucleic acid is substantially free of sequences that naturally 
flank the nucleic acid (i.e., sequences located at the 5' and 3' 
45 ends of the nucleic acid) in the genomic DNA of the organism 
from which the nucleic acid is derived. Moreover, an "iso-
lated" nucleic acid molecule can be substantially free of other 
cellular material, or culture medium when produced by 
recombinant techniques, or chemical precursors or other 
50 chemicals when chemically synthesized. (see, Sambrook et 
al. 1989, Molecular Cloning: A Laboratory Manual. 2nd, ed., 
Cold Spring Harbor Laboratory, Cold Spring Harbor Labo-
ratory Press, Cold Spring Harbor, N.Y.). 
The probe typically comprises substantially purified 
55 nucleic acid. The nucleic acid probe typically comprises a 
region of nucleotide sequence that hybridizes to at least about 
10, 11,12, 13, 14, 15, 16,17, 18, 19,20,21,22,23,24,25,26, 
27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, or 90 consecutive 
nucleotides of a target nucleic acid. The target nucleic acid 
be for example a Cy3 fluorophore. In embodiments wherein 
the resonance energy transfer signal is due to fluorescence 
resonance energy transfer, the acceptor moieties can be a Cy5 
fluorophore. Additional examples of FRET donor and accep-
tor moieties useful in the present invention are provided 
below. If acceptor and donor fluorophores are well matched, 
excitation of the donor can be achieved at a wavelength that 
has little or no capacity to excite the acceptor; excitation of the 
acceptor will therefore only occur if both nucleic acid probes 65 
are hybridized to the same target nucleic acid and FRET 
60 can be a sense strand of one of the target nucleic acid 
sequences, an anti-sense sequence, or naturally occurring 
mutants thereof. Preferably, the nucleic acid target is an 
mRNA. 
Probes based on the nucleotide sequences can be used to 
detect or amplify transcripts or genomic sequences encoding 
the same or homologous proteins. In other embodiments, the 
probe further comprises a label group attached thereto, e.g., occurs. 
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the label group can be a radioisotope, an enzyme, or an 
enzyme co-factor. Such probes can be used as a part of a 
genomic marker test kit for identifying cells which express a 
particular protein, such as by measuring a level of the protein-
encoding nucleic acid in a sample of cells, e.g., detecting the 5 
target nucleic acid mRNA levels or determining whether the 
gene encoding the mRNA has been mutated or deleted. 
In an additional preferred embodiment, an isolated nucleic 
acid molecule of the invention comprises a nucleic acid probe 
sequence that hybridizes, e.g., hybridizes under stringent 10 
conditions, to a target nucleotide sequence of interest. These 
hybridization conditions include washing with a solution 
having a salt concentration of about 0.02 molar at pH 7 at 
about 60° C. As used herein, the term "hybridizes under 
stringent conditions" is intended to describe conditions for 15 
hybridization and washing under which nucleotide sequences 
at least 60% homologous to each other typically remain 
hybridized to each other. Preferably, the conditions are such 
that sequences at least about 65%, more preferably at least 
about 70%, and even more preferably at least about 75% or 20 
more homologous to each other typically remain hybridized 
to each other. Such stringent conditions are known to those 
skilled in the art and can be found in Current Protocols in 
Molecular Biology, John Wiley & Sons, N.Y. (1989) 6.3.1-
6.3.6. A preferred, non-limiting example of stringent hybrid- 25 
ization conditions are hybridization in 6x sodium chloride/ 
sodium citrate (SSC) at about 45° C., followed by one or more 
washes in0.2xSSC, 0.1 % SDS at 50-65° C.As used herein, a 
"naturally-occurring" nucleic acid molecule refers to an RNA 
or DNA molecule having a nucleotide sequence that occurs in 30 
nature (e.g., encodes a natural protein). 
The nucleic acid probes of the invention can be DNA or 
RNA or chimeric mixtures or derivatives or modified versions 
thereof, so long as it is still capable of hybridizing to the 
desired target nucleic acid. In addition to being labeled with a 35 
resonance energy transfer moiety, the nucleic acid sequence 
can be modified at the base moiety, sugar moiety, or phos-
phate backbone, and may include other appending groups or 
labels, so long as it is still capable of priming the desired 
amplification reaction, or functioning as a blocking oligo- 40 
nucleotide, as the case may be. 
Nucleic acid probes of the invention may be synthesized by 
standard methods known in the art, e.g. by use of an auto-
mated DNA synthesizer (such as are commercially available 
from Biosearch, Applied Biosystems, etc.). As examples, 45 
phosphorothioate oligonucleotides may be synthesized by 
the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), 
methylphosphonate oligonucleotides can be prepared by use 
of controlled pore glass polymer supports (Sarin et al., 1988, 
Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc. 50 
Once the desired oligonucleotide is synthesized, it is 
cleaved from the solid support on which it was synthesized 
and treated, by methods known in the art, to remove any 
protecting groups present. The oligonucleotide may then be 
purified by any method known in the art, including extraction 55 
and gel purification. The concentration and purity of the oli-
gonucleotide may be determined by examining oligonucle-
otide that has been separated on an acrylamide gel, or by 
measuring the optical density at 260 nm in a spectrophotom-
eter. 60 
Suitable moieties that can be selected as donor or acceptors 
in FRET pairs are set forth below: 
4-acetamido-4'-isothiocyanatostilbene-2,2'disulfonic 
Acridine and Derivatives 
acridine 
acridine isothiocyanate 
Acid 
65 
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5-(2'-aminoethyl)aminonaphthalene-l-sulfonic acid 
(ED ANS) 
4-amino-N-[3-viny lsulfony !)phenyl ]naphthalimide-3, 
5disulfonate(LuciferYellow VS) 
N-( 4-anilino-1-naphthyl)maleimide 
Anthranilamide 
Brilliant Yellow 
coumarin and derivatives: 
coumarm 
7-amino-4-methylcoumarin (AMC, Coumarin 120) 
7-amino-4-trifluoromethylcoumarin (Coumarin 151) 
cyanosine 
4 '-6-diaminidino-2-pheny lindole (DAPI) 
5' ,5 "-dibromopyrogallol-sulfonephthalein (Bromopyro-
gallol Red) 
7 -diethy lamino-3-( 4 '-isothiocyanatophenyl )-4-methyl-
coumarin diethylenetriamine pentaacetate 
4-( 4 '-diisothiocyanatodihydro-stilbene-2,2'-disulfonic 
acid 
4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid 
5-[ dimethylamino ]naphthalene-1-sulfonyl chloride (DNS, 
dansyl chloride) 
4-( 4'-dimethylaminophenylazo )benzoic acid (DABCYL) 
4-dimethylaminophenylazophenyl-4'-isothiocyanate 
(DAB ITC) 
Eosin and Derivatives: 
eosm 
eosin isothiocyanate 
Erythrosin and Derivatives: 
erythrosin B 
erythrosin isothiocyanate 
ethidium 
Fluorescein and Derivatives: 
5-carboxyfluorescein (FAM) 
5-( 4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF) 
2'7'-dimethoxy-4' 5'-dichloro-6-carboxyfluorescein (J 0 E) 
fluorescein 
fluorescein isothiocyanate 
QFITC (XRITC) 
fluorescamine 
IR144 
IR1446 
Malachite Green isothiocyanate 
4-methy lumbelliferone 
ortho cresolphthalein 
nitrotyrosine 
pararosaniline 
Phenol Red 
B-phycoerythrin 
o-phthaldialdehyde 
Pyrene and Derivatives: 
pyrene 
pyrene butyrate 
succinimidyl 1-pyrene butyrate 
Reactive Red 4 (Cibacron® Brilliant Red 3B-A) 
Rhodamine and Derivatives: 
6-carboxy-X-rhodamine (ROX) 
6-carboxyrhodamine (R6G) 
lissamine rhodamine B sulfonyl chloride 
rhodamine (Rhod) 
rhodamine B 
rhodamine 123 
rhodamine X isothiocyanate 
sulforhodamine B 
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sulforhodamine 101 
sulfonyl chloride derivative ofsulforhodamine 101 (Texas 
Red) 
N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA) 
tetramethyl rhodamine 
tetramethyl rhodamine isothiocyanate (TRITC) 
riboflavin 
rosolic acid 
terbium chelate derivatives 
Alexa Derivatives 
Alexa-350 
Alexa-488 
Alexa-547 
Alexa-647 
In yet another embodiment, the magnetic nanoparticle 
probes of the invention may be further labeled on the biocom-
patible coating surface with any other art-known detectable 
marker, including a radioisotope, such as 32P, 35S, 3 H, and the 
like; a fluorescent dye; an organic bead with fluorescent or 
luminescent characteristics; an inorganic bead with fluores-
cent or luminescent characteristics; and enzymatic markers 
that produce detectable signals when a particular chemical 
reaction is conducted, such as alkaline phosphatase or horse-
radish peroxidase. Such enzymatic markers are preferably 
heat stable, so as to survive the denaturing steps of the ampli-
fication process. Magnetic nanoparticle probes may also be 
indirectly labeled on the biocompatible coating surface by 
incorporating a nucleotide linked covalently to a hapten or to 
22 
multiple probes for single or multiple intracellular targets in a 
single vesicle. In certain preferred embodiments, multiple 
magnetic nanoparticle probes with multiple target sequences 
are designed to target delivery and imaging for disease detec-
tion and drug monitoring using the vesicle design. In certain 
preferred embodiments for single or multiple magnetic nano-
particle probes, this encapsulation embodiment may allow us 
to effectively monitor multiple targets simultaneously either 
using a single imaging technique or some combination of 
10 
multimodality imaging (any combination of MRI, nuclear 
imaging, and optical imaging); to improve the stability of the 
magnetic nanoparticle probe compositions; to reduce non-
specific interactions of the magnetic nanoparticle probe com-
15 positions in the blood stream; and to increase the life time of 
circulation of our magnetic nanoparticle probe compositions. 
The inclusion of more than one delivery ligand and/or more 
than one targeting ligand on the surface of such vesicle-
encapsulated magnetic nanoparticle probe composition may 
20 increase the effective targeting of tissues, diseased cells, and 
infected cells, and will allow the effective control of the 
concentration of delivered magnetic nanoparticle probes 
which many improve significantly the signal to noise ratio. In 
certain embodiments, such encapsulation may also facilitate 
25 the delivery of magnetic nanoparticle probe compositions for 
multimodality imaging applications. Specifically, a magnetic 
nanoparticle probe may have multimodality imaging abili-
ties, or the vesicle surface may also be modified to include 
a molecule such as biotin, to which a labeled avidin molecule 
may be bound, or digoxygenin, to which a labeled anti- 30 
digoxygenin antibody may be bound. 
such abilities. 
As illustrated in FIG. 1 C, in other embodiment of the above 
design of magnetic nanoparticle probes, it may be advanta-
geous to encapsulate the entire magnetic nanoparticle probe 
or multiple magnetic nanoparticle probes, both nucleic acid 
The magnetic nanoparticle probes of the invention have use 
in nucleic acid and polypeptide detection. Accordingly, the 
magnetic nanoparticle probes of the invention can be used in 
methods of diagnosis, wherein a sequence is complementary 
to a sequence (e.g., genomic) of an infectious disease agent, 
e.g. of human disease including but not limited to viruses, 
bacteria, parasites, and fungi, thereby diagnosing the pres-
ence of the infectious agent in a sample of nucleic acid from 
a patient. The subject nucleic acid can be genomic or cDNA 
or mRNA or synthetic, human or animal, or of a microorgan-
ism, etc. 
35 and protein targeting probes in a vesicle. As used herein, the 
term "vesicle" refers to a biocompatible coating selected 
from the group consisting of a lipid bilayer, a mesoporous 
solid (e.g. mesoporous silica, polymer, or any combination 
thereof) or dendrimers. The vesicles of the present invention 
40 may be targeted to a specific type of cell or tissue using a 
combination of a delivery ligand and a targeting ligand as 
described above. In a further preferred embodiment the in 
vivo delivery of the probe-containing vesicles do not illicit a 
significant immune response. This effect may be provided by 
The present invention also provides methods for determin-
ing the expression of a subject nucleic acid, comprising intro-
ducing the magnetic nanoparticle probe composition of the 
present invention to a sample suspected of containing the 
subject nucleic acid; and detecting the presence of the subject 
nucleic acid by intracellular molecular imaging. The present 
invention provides the detection of the presence of the subject 
nucleic acid is measured by magnetic resonance imaging 
(MRI), or the detection may be determined by optical imag-
ing, measuring resonance energy transfer signals. In one 
embodiment, the methods are performed in vivo. In a pre-
ferred embodiment, the sample contains a living cell, a living 
animal, and/or a patient. In certain embodiments, the compo- 55 
sition is introduced into may be delivered into shallow or deep 
tissue of the patient by injection, inhalation, intranasal admin-
istration, oral administration, sublingual administration, buc-
45 a biocompatible coating (e.g. PEG-based coating) on the 
outer exposed surface of the vesicle. In a further preferred 
embodiment, the capsule material is biodegradable, and fast 
release of probes from the capsule can be achieved due to 
reduction or light activable decay (UV, visible, or infrared 
50 light) of the capsule material. In certain embodiments some 
drug molecules may also be encapsulated along with the 
probes to allow for monitoring of the drug activities and the 
effect of treatment. 
In one embodiment the inventors provide a useful screen-
ing tool for drug discovery where a rapid specific and sensi-
tive assay can detect in vivo changes in the expansion role of 
protein transcripts of interest, either at a steady state or in 
response to the administration of drug candidates. In another 
embodiment that can be used in the diagnosis or prognosis of 
a disease or disorder, the target sequence is a naturally occur-
ring or wild type human genomic or RNA or cDNA sequence, 
mutation of which is implicated in the presence of a human 
disease or disorder, or alternatively, the target sequence can 
be the mutated sequence. In such an embodiment, optionally, 
cal administration, topical administration, local delivery to 
tissue, or direct delivery into blood stream. In a further pre- 60 
ferred embodiment, the composition is introduced by subcu-
taneous injection, intravenous injection, intradermal injec-
tion, intramuscular injection, or microinjection. Further in 
animal systems, probe may be delivered using tail vein injec-
tions. 65 the amplification reaction can be repeated for the same 
sample with different sets of probes that amplify, respectively, 
the naturally occurring sequence or the mutated version. By 
In certain embodiments as illustrated in FIG. lC, it may be 
significantly advantageous to encapsulate the single probe or 
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way of example, the mutation can be an insertion, substitu-
tion, and/or deletion of one or more nucleotides, or a trans-
location. 
In one embodiment, the detection of the subject nucleic 
acid indicates the presence of a cancer in the sample. In a 
preferred embodiment, the subject nucleic acid comprises 
K-ras, survivin, p53, p16, DPC4, or BRCA2. In other 
embodiments, the detection of the subject nucleic acid indi-
cates an alteration of the expression pattern of the subject 
nucleic acid in response to an external stimulus or indicates 10 
the presence of a virus in the sample. 
The invention further provides methods for producing a 
magnetic nanoparticle probe composition for facilitating 
molecular imaging, comprising combining a magnetic nano-
particle with a biocompatible coating; adding a peptide ligand 15 
that is capable of facilitating the traverse of a cell membrane; 
and adding a nucleic acid probe. In some embodiments, the 
magnetic nanoparticle probe composition further comprises 
the step of adding a second ligand for targeting the composi-
tion to a particular type of cell or tissue. 20 
In one embodiment of the present invention, the nucleic 
acid probe hybridizes to a nucleic acid target sequence on a 
subject nucleic acid and forms a stem-loop structure when not 
bound to the nucleic acid target sequence. In another embodi-
ment, the nucleic acid pro be hybridizes to a nucleic acid target 25 
sequence on a subject nucleic acid and has a linear or ran-
domly coiled structure when not bound to the nucleic acid 
target sequence. In yet another embodiment, the nucleic acid 
probe comprises a modification of the nucleic acid backbone. 
The invention further provides that these methods may com- 30 
prise the use of a nucleic acid probe that incorporates a reso-
nance energy transfer moiety. 
In certain other embodiments of the present invention, 
several magnetic nanoprobes (4-6) will be hybridized on the 
same target. This could lead to an increased sensitivity and 35 
signal-to-noise ratio. In other embodiments, each magnetic 
nanoprobe can comprise a hairpin probe and two magnetic 
nanoparticles at the end of the stem. 
In addition to MRI-based contrast generation based on the 
clustering of two or more magnetic nanoparticles as a result of 40 
hybridization of nucleic acid probes, the same contrast gen-
eration strategies can be developed to detect polypeptide 
expression or protein-protein interactions between known 
pairs of proteins both in biochemical, cellular and in vivo 
molecular imaging assays. In a preferred embodiment, a 45 
nanoparticle probe composition comprises a first magnetic 
nanoparticle probe composition comprising a first polypep-
tide probe, a delivery ligand, and a detectable moiety; and a 
second magnetic nanoparticle probe composition comprising 
a second polypeptide probe, a delivery ligand, and a detect- 50 
able moiety, wherein the detectable moiety comprises a mag-
netic nanoparticle having a biocompatible coating thereon; 
wherein the first polypeptide probe hybridizes to a first target 
sequence and the second polypeptide probe hybridizes with a 
second target sequence; and wherein an effect on water relax- 55 
ation from interaction between the first and second magnetic 
nanoparticles can be detected to determine hybridization of 
both the first and the second targeting probes to the first and 
the second target. In one preferred embodiment, the first and 
second polypeptide probes bind to the same target polypep- 60 
tide. In another preferred embodiment, the first and second 
polypeptide probes bind to a first and second target polypep-
tide respectively, such that when the two target polypeptides 
interact, the first and the second nanoparticle probe compo-
sitions are brought in close proximity and generate a measur- 65 
able effect on water relaxation. The present invention pro-
vides that in a preferred embodiment, the polypeptide probe 
24 
comprises an antibody or antibody fragment and may be 
attached to the biocompatible coating of the magnetic nano-
particle probe to target a pair of proteins, as illustrated in FIG. 
2B. In other embodiments, effective targeting of protein com-
plexes in living cells can be achieved by using other high 
affinity ligands conjugated to the surface coating of magnetic 
nanoparticles such as FIAsh or ReASH for tetra cysteine 
(Cys) tags or Ni for Poly Histidine (His) tags genetically 
engineered on target proteins. The magnetic contrast can be 
generated based on targeting of two or more magnetic nano-
particles to the protein complexes. This targeting of magnetic 
nanoparticles to proteins can be achieved by using antibodies, 
antibody fragments, peptides, or other high affinity ligands 
(e.g. Nickel for Poly Histidine tags, GST for Glutathione, etc) 
attached to the surface of the magnetic nanoparticle biocom-
patible coating. This magnetic imaging ability can also be 
combined with fluorescence based measurements using tra-
ditional FRET pairs or Lanthanide based FRET measure-
ments. 
In a preferred embodiment antibody or antibody fragment 
may provide advantages as compared to other high affinity 
ligands for in vivo detection of protein interaction or protein 
complexes especially in human subjects, since the use of 
other high affinity ligands requires modification of the pro-
teins, which may only be possible for solution, cellular or 
animal studies. In certain embodiments other probe mol-
ecules such as peptides and aptamers may be incorporated on 
the surface of the magnetic nanoparticle for protein interac-
tion studies. 
The present invention is based on magnetic nanoparticle 
induced changes in water relaxation. In the presence of a 
paramagnetic substance, the water relaxation properties, 
namely T1 , T2 and T2 *(l/T2 *=l/T2 +l/T2 ', with T2 ' being a 
time constant arising from magnetic field inhomogeneity) of 
proton nuclear spins are shortened to some extent. In a pre-
ferred embodiment, paramagnetic or superparamagnetic 
nanoparticle probes are used to detect specific nucleic acids in 
tissues and cells, since superparamagnetic iron oxides (SPIO) 
or superparamagnetic nanoparticles affect the relaxation 
times in a more significant way. 
In certain preferred embodiments, the uniformity of the 
size of the magnetic nanoparticles is required. There is a 
strong dependence of water relaxivity on nanoparticle size, 
with smaller particles having lower relaxivity and a lower 
ratio of RiR1 (R1 =1/T u R2 =1/T 2). The relaxivity also 
depends on the strength of applied magnetic field. For nano-
particles of-5 nm in size and the field strength of3 Tesla, an 
R2 value of 40(s mM(Fe)f 1 is expected withmonodispersed 
nanoparticle probes. When the nanoparticle probes are bound 
to the mRNA target such that a pair of magnetic nanoparticles 
is clustered together, an R2 of 100 (s mM(Fe)f 1 is antici-
pated. This leads to an increase of the R2 value by 60 (s 
mM(Fe )f 1. Assuming the tissue intrinsic T 2 to be 80 ms, a 
100 nM Fe concentration introduced by the nanoparticle 
probes may lead to a T 2 of 60 ms and 40 ms respectively with 
bound and unbound nanoparticle probes. This difference in 
T, should be sufficient for clinical imaging applications. 
In yet another embodiment, the dependence ofT 2 on nano-
particle size will be determined. According to the theoretical 
prediction (Koenig and Kellar, 1995) and experimental mea-
surement (Pouliquen et al, 1992), R2 approximately doubles 
when the particle is increased from 5-10 nm to 9-15 nm (FIG. 
6). When the magnetic nanoparticle probes hybridize with 
targeted mRNA in vivo, this increase in size will be effec-
tively achieved. For illustrative purposes, assume that the 
nanoprobe delivery achieves an in vivo concentration of 50 
µM of iron (ca. 25 nM of nanoparticle probes), and that at 3 T 
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the value of T 2 of the tissue is about 100 ms without contrast 
agent. In the presence of mRNA targets, hybridization 
between the magnetic nanoparticle probes and the mRNA 
targets may lead to a T 2 of 48 ms. Even if only half of the 
nano pro bes are hybridized (corresponding to a target concen-
tration of 12.5 nM), there will be an increase inrelaxivitythat 
reduces T2 to 35 ms. With a spin-echo imaging sequence 
using a TE of 50 ms, a -30% contrast will be achieved, which 
is sufficient for visualizing the corresponding cells or tissue. 
EXAMPLES 
Synthesis and Characterization of Magnetic Nanoparticles 
10 
26 
tion. Both oxide nanoparticles with magnetization in the 
range 5-12 emu/g and metallic nanoparticles capped with a 
protective coating and with magnetization in the range of 
500-800 emu/g can be synthesized. The iron oxide core size 
and its distribution can be determined by high-resolution 
transmission electron microscopy (TEM), while the biocon-
jugated particles can be characterized by using dynamic light 
scattering, which measures the hydrodynamic radius of 
nanometer-sized particles in solution. 
In the studies to be described, magnetic iron oxide nano-
particles (MIONs) with chemical composition Fe3 0 4 synthe-
sized using the reverse micelle technique were provided by 
Dr. Charles O'Connor at the University of New Orleans. 
These MIONs had an average size of 6.6 nm with a size 
Example 1 15 distribution of 11 % as determined by transmission electron 
microscopy, as shown in FIG. 3 (personal communication, 
Dr. Charles O'Connor). Due to the synthesis approach, these 
particles have a residual capping of surfactant molecules such 
as cetyltrimethylammonium bromide (CTAB), which render 
Compared with micrometer sized magnetic particles and 
chelates of paramagnetic ions such as gadolinium diethylen-
etriaminopentaacetic acid (Gd-DTPA), magnetic nanopar-
ticles are much more efficient as relaxation promoters, and 
their effect on the relaxivities of water is measurable even at 
nanomolar concentrations, as demonstrated theoretically and 
experimentally (Koenig et al., 1995; Bulte et al., 1992; Le 
Due, 2001; Josephson et al., 2001; Perez et al., 2002). Spe- 25 
cifically, the use of ferromagnetic and superparamagnetic 
nanoparticles as contrast agents can induce a more than 10 
fold increase in proton relaxivities (Coroiu et al., 1999). 
Based on the enzyme-cleavable contrast agents reported by 
Meade and coworkers (Louie et al., 2000; Huber et al., 1998), 30 
magnetic relaxation by gadolinium atoms is a short-range 
effect. The presence of a carbohydrate cap (less than 1 nm 
thick) prevents water molecules from contacting the contrast 
agent Gd (HP-D03A). In contrast, superparamagnetic nano-
particles (2-3 nm core size) are often coated by a thickdextran 35 
layer (10-20 nm) (Josephson et al., 2001). Despite this coat-
ing, the encapsulated nanoparticles are highly efficient con-
trast agents, yielding considerably stronger effects than gado-
linium compounds. Although it is possible that water 
molecules are able to penetrate the dextran layer, iron oxide 40 
nanoparticles are thought to function over a distance range of 
approximately 2-20 nm. 
To facilitate probe/target hybridization and signal trans-
duction, the size of the magnetic nanoparticle with coating 
should be minimized. Means of obtaining highly monodis-
persed particles are known in the art. For example, the par-
ticles can be synthesized by (i) chemical reduction ofFeC12 
and FeCl3 compounds according to published procedures 
(Shen et al., 1993 ). Alternatively, the magnetic nanoparticles 
can be synthesized by (ii) precipitation within the confines of 
a polymer matrix following an ion-exchange procedure (Mal-
louk et al., 1996, Chem. Mater. 8:2121-2127), or by (iii) 
precipitation within micelles (Feltin and Pileni, 1997; Seip 
and O'Connor, 1999). Of these three methods, precipitation 
within micelles is the method of choice because it yields 
magnetic nanoparticles in the desired size range with a nar-
row size distribution. 
In the reverse micelle method, the precipitation of mag-
netic nanoparticles is confined to aqueous droplets suspended 
20 these particles soluble only in organic solvents and also pre-
vent aggregation of nanoparticles. Particles used in this study 
were dispersed in toluene and were insoluble in water prior to 
modification. 
Example 2 
Encapsulation of the Magnetic Nanoparticles 
A critical component for the success of this invention is to 
make monocrystalline iron oxide nanoparticles (MIONs) 
water-soluble and create a stable suspension ofMIONs that 
are biocompatible and surface-functionalized. A standard 
approach in the field is to use the polysaccharide dextran. A 
distinct disadvantage to this approach is the large thickness of 
the coating (approximately 15 nm). In order to minimize 
steric hindrance in hybridization between two probes, it is 
crucial to minimize the size of the coating. Therefore, efforts 
in the present invention were focused on developing alterna-
tive coatings. Two such post-synthesis coating processes will 
be described in detail here. 
The first coating uses the monolayer ligand 16-mercapto-
hexadecanoic acid (Liu and Xu 1995). The MIONs were 
reacted with the organic surfactant 16-mercaptohexade-
canoic acid (MHA). MHAhas a carboxylic head group at one 
45 end of the molecule that reacts with the surface of the nano-
particle. The other end of MHA terminates with a thiol head 
group, which provides a reactive functionality to which modi-
fied oligonucleotides can be attached. Reaction ofMHA with 
MIONs resulted in a self-assembled monolayer film with 
50 exposed, reactive sulfhydryls on the surface of the particle. 
Since the coating is only a single layer of MHA molecules, 
this should increase the diameter of the particles by approxi-
mately 1.6 nm, since MHA is a chain of 15 carbon atoms. A 
colorimetric assay based on 5,5-dithiobis(2-nitrobenzoic) 
55 acid was used to confirm the presence of exposed sulflhydryl 
groups (Sedlak and Lindsay, 1968, Anal. Biochem. 25:192-
205), which facilitates the conjugation of modified oligo-
nucleotides to MIONs. 
in an immiscible phase, e.g. hydrocarbons. Since the precipi- 60 
tation reaction is entirely confined to nanometer sized water 
droplets, the size and shape of the nanoparticle depends on the 
characteristics of the oil-water mixture. The droplets are 
formed by emulsifying water into a continuous oil phase 
through the use of surfactants to lower surface energy 65 
between the otherwise immiscible phases. The surfactant 
monomers self-assemble into micelles at a critical concentra-
The second coating to be described in detail here exploits 
the amphiphilic nature of a phospholipid-polyethylene glycol 
(PEG) molecule (FIG. 4). Mixtures of 1,2-Distearoyl-sn-
Glycero-3-Phosphoethanolamine Polyethylene Glycol 2000 
(DSPE-PEG 2000) and 1,2-Distearoyl-sn-Glycero-3-Phos-
phoethanolamine-N-[Amino(Polyethylene Glycol) 2000] 
(DSPE-PEG 2000 Amine) were dissolved in chloroform (1 :8 
ratio ofDSPE-PEG 2000:DSPE-PEG 2000Amine) to a total 
concentration of 1.4 mM, and iron oxide was added to the 
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solution at a concentration of 0.33 mg/ml. This surfactant/ 
iron oxide solution was then dried under argon gas and left in 
a vacuum dessicator for 48 hours to remove all traces of 
organic solvents. The dried film was then easily resuspended 
in deionized water with agitation. The solution obtained was 5 
filtered using 0.2 µm syringe filters to remove aggregates. The 
resulting filtered solution (referred to as micelle-MION s) was 
free from cloudiness and is stable for a period of weeks when 
kept at 4° C. to prevent bacterial growth. This coating pro-
vides biocompatibility and enhances solubility of the 10 
MIONs. It also has the added advantage of flexible function-
ality, since a number of modified PEGs other than PEG-amine 
are readily available (e.g. PEG-maleimide). 
To determine the size of the micelle-coated MIONs, 
dynamic light scattering (DLS) using a DynaPro-LSR instru- 15 
ment from Protein Solutions was employed. By fitting the 
data to a poly dispersed model (Braginskaya et al. 1983) using 
the Dynamics software (version 5.26) provided with the 
instrument, the average hydrodynamic radius of the micelle-
MIONs is 19.3mn±3 mn, whichaccountsfor93%ofthemass 20 
of the sample (FIG. 5). 
Example 3 
25 
Bioconjugation of Magnetic Nanoparticles to Create Multi-
functional Probes for Imaging and Delivery 
After encapsulation, the particles can be conjugated to 
peptides, proteins, fluorescent dye molecules, and hairpin 
oligonucleotide (ODN). Such conjugation is achieved by uti- 30 
lizing the functional group on the surface of the MIONs (in 
the specific cases described here, either reactive sulfhydryls 
or amines). These functional groups on the particle surface 
can be covalently conjugated to any of the above-described 
moieties by using standard cross-linking chemistry. Below 35 
will be described two specific examples of bioconjugation 
between MIONs and a) delivery peptide plus fluorescent dye 
and b) oligonucleotides. These examples use micelle-MIONs 
and MHA-MIONs, respectively; however, the coatings are 
versatile and either application is possible with both types of 40 
particles, with the micelle-MIONs being the preferred 
embodiment due to their superior solubility. 
28 
media formulation provided by Cambrex (New Jersey) was 
added to cells and incubated for an hour. Cells were washed in 
PBS buffer two times and imaged using a Zeiss confocal 
microscope ((data not shown)). MDBK cells were treated 
similarly. 
To further validate the delivery of the micelle-MIONs into 
live MDBK cells, T2 relaxation times were measured and 
MRI contrast images were obtained. For T 2 measurements, a 
Bruker Minispec Analyzer MQ20was used. Cells were grown 
in a T25cultureplate (approximately 106 cells) and then incu-
bated with a 1:4 dilution ofmMIONs and media (as above). 
After 1 hour of incubation, cells were washed two times with 
PBS buffer and trypsinized to remove the cells from the plate. 
Cells were resuspended in a final volume of 1.5 ml of media. 
500 ul of cell suspension was placed in a 10 mm sample tube 
for T 2 measurements. T 2 values were determined using the 
cpmb sequence. T 2 relaxation time determined for cells with 
mMIONs was 623±2 ins; T 2 relaxation time for cells without 
mMIONS was 1503±20 ms (See FIG. ll(a)). Controls for 
this experiment were MDBK cells without mMION incuba-
tion. This cell sample was then imaged on a 3T Siemens MRI 
system, and good contrast was obtained for the cells that 
contained micelle-MIONs (FIG. ll(b)). 
The second bioconjugation scheme to be described 
employs MIONs coated with MHA and linked to oligonucle-
otides. Initial studies with MIONs were designed to detect 
hybridization between two single-stranded oligonucleotides 
(30-mers) (FIG. 7). For these solution studies, MHA-coated 
MIONs were attached to complementary oligonucleotides 
via reaction with their surface sulfhydryl groups. Again, the 
heterobifunctional cross-linker SPDP was used for the bio-
conjugation due to its amine and sulfhydryl reactivity. Two 
complementary oligonucleotides were designed with reactive 
primary amine groups on their 3' and 5' end, respectively. 
Their specific sequences are: Probe 1: /Cy3/-5'-GAGTCCT-
TCCACGATACTACGATCCACATT-3' (SEQ ID N0:27), 
Probe 2: /Cy5/-5'-AATGTGGATCGTAGTATCGTCGAAG-
GACTC-3' (SEQ ID N0:28). 
These oligonucleotides were first coupled to SPDP and 
then reacted with MHA-coated MIONs that were reduced 
with TCEP to eliminate any disulfide bonds that might be on 
the surface. The quantity of oligonucleotides to react was 
determined by approximating the molar concentration of par-
ticles and then reacting oligonucleotides and MIONs in a 1 :1 
For optical imaging and efficient delivery of magnetic 
nanoparticles, the functionalized lipid-PEG molecules 
(DSPE-PEG-amine) in the micelle structure were targeted for 
bioconjugation. Simultaneous attachment of fluorescent dye 
molecules and a delivery peptide on micelle-MION s through 
45 or 2: 1 ratio to ensure that there was on the order of one 
a reactive amine group was achieved using the strategy shown 
in FIG.10. Texas Red STP ester (1 µm) and the heterobifunc-
tional cross-linking reagent, N-succinimidyl 3-(2-py- 50 
ridyldithio )propionate (SPDP) (10 µm) were used to react 
with amine groups on the micelle-MIONs. This mixture was 
allowed to react for 2 hours. The reductant tris(2-carboxy-
ethyl) phosphine hydrochloride (TCEP) was added at 20 mM 
to reduce the thiol group on SPDP for 1 hour. A Microcon 55 
YMl 0 filter unit was used to remove unreacted TxRed and 
TCEP. Tat peptide-6-Amino hexonic acid-Cys (for delivery) 
was reacted overnight with the mMIONs via the SPDP cross 
linker at a concentration of 1 µM. Unreacted peptide was 
removed by dialysis into 2 L of PBS buffer using a Slide-A- 60 
Lyzer Dialysis Cassette (MWCO 10000) for 4 hours. 
The mMION s with both TxRed and TAT peptide attached 
were successfully delivered into human dermal fibroblast 
(HDF) cells and kidney-derived MDBK cells (data not 
shown). HDF cells were plated on 8-well Nalgene Nurre cell 65 
culture plate and allowed to grow for 48 hours. A 1 :4 dilution 
of the original mMIONs-Tx Red-peptide complex in FBM2 
oligonucleotide per nanoparticle. This conjugation was suc-
cessfully completed as shown by the ability to separate free 
oligonucleotides from particles both by filtration and mag-
netically. The resulting solution contained fluorescent par-
ticles that behave similarly to unlabeled MIONs, indicating 
the successful attachment of oligonucleotides with fluoro-
phores. These MIONs conjugated to oligonucleotides were 
then used in the study described in the following section. 
Example 4 
Magnetic and Optical Effects of the Close Proximity of Two 
Multifunctional Magnetic Nanoparticle Probes 
To detect the hybridization of oligonucleotides attached to 
MHA-MIONs, a FRET (Fluorescence Resonance Energy 
Transfer) based assay was developed (FIG. 7). The approach 
of FRET is based on energy transfer between the donor and 
the acceptor fluorophores. This process of energy transfer is 
only efficient if two fluorophores are in close proximity to 
each other (approximately 5 mn or less). This technique has 
been used to detect hybridization of oligonucleotides in con-
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ventional biochemical studies. For the development of this 
assay, complimentary oligonucleotides modified at the 3' end 
and 5' end with a FRET dye pair, Cy3 and Cy5, were attached 
to MHA-MIONs to produce Cy3-MION and Cy5-MION, 
respectively. The energy transfer from the donor (Cy3- 5 
MION) to the acceptor (Cy5-MION) is detected upon hybrid-
ization. 
For the hybridization assay, Cy3-MION and Cy5-MION 
were mixed together (Cy3-MION+Cy5-MION). For the 
FRET studies, we maintained a constant oligonucleotide con-
centration for all samples (Cy3-MION, Cy5-MION, and 
Cy3-MION+Cy5-MION). All samples were excited at 500 
nm to eliminate any significant direct excitation of the Cy5 
dye. The emission wavelength was scanned from 570 nm-700 
nm. The emission peak for the Cy3 dye is 570 nm, and for the 
Cy5, it is 67 5 nm. A representative FRET dataset is shown in 
FIG. 8. In the Cy3-MION+Cy5-MION sample, the Cy3 sig-
nal intensity has decreased and the Cy5 signal has increased 
relative to the individual samples (Cy3-MION, Cy5-MION). 
The signal intensity detected in this assay was much lower 20 
than the signal intensity detected in standard hybridization 
studies using oligonucleotide pairs, due to steric hindrance of 
the MION coated particles and also the stringent requirement 
10 
15 
to have 1-2 oligonucleotides per particle. The FRET study 
results indicated that the complementary oligonucleotides of 25 
the Cy3-MION+Cy5-MION sample were hybridized. 
Magnetic Resonance Imaging (MRI) Contrast agents such 
30 
MION). Even though the samples initially had the same con-
centration of MION particles for conjugation of the oligo-
nucleotides, there are small variations in concentration of the 
two samples (Cy3-MION, Cy5-MION). The MRI results are 
shown in Table 1. The results clearly indicate a shift in the T2 
relaxation time (ins) of the Cy3-MION Cy5-MION as com-
pared to the Cy3-MION and Cy5-MION samples. 
TABLE 1 
Trial 1 Trial 2 
Sample T2 (ms) T2 (ms) 
Cy3-MION 920.4 546.1 
Cy5-MION 726.4 469.2 
CY3-MION + CY5-MION (predicted) 823.4 507.65 
CY3-MION + CY5-MION (obtained) 713.8 426.9 
It is predicted that the T 2 value of the Cy3-MION+Cy5-
MION sample will be lower than that of the individual 
samples (Cy3-MION, Cy5-MION) because hybridized 
sample of oligonucleotides will bring the MIONs in close 
proximity, effectively increasing their local magnetic field 
strength and thus affecting their relaxation behavior. 
To develop more quantitative understanding of the 
response ofT 2 relaxivities as a function of MI ON concentra-
tion, the T 2 relaxivities of a serial dilution of the MION 
sample were measured, and a calibration curve for T 2 relax-
ation times vs. MION (Fe) concentration was developed. The 
calibration plot is shown in FIG. 9. Based on this standard 
as the one described in this invention are often used in MRI to 
enhance lesion detection. For clinical diagnostic imaging, 
paramagnetic substances such as chelates of gadolinium are 
frequently used as contrast agents. In the presence of such a 
paramagnetic substance, the relaxation properties, namely 
T1 , T2 and T2 * (l/T2 *=l/T2 +l/T2 ', with T2 ' being a time 
constant arising from magnetic field inhomogeneity) of pro-
ton nuclear spins are shortened to some extent. Theoretically, 
protonrelaxivities R1=1/T 1 andR2 =1/T2 change with the size 
of magnetic nanoparticles (Koenig et al., 1995) as illustrated 
30 curve, the response in T 2 relaxation times was estimated for 
the CY3-MION+CY5-MION sample, as compared to the 
individual samples (Cy3-MION, Cy5-MION). The results 
are shown in FIG. 9. The results of the comparison show a 
significant shift in the effective concentration of the MION 
by FIG. 6(a) in which R1 and R2 profiles were predicted for 
magnetic nanoparticles of 6, 9 and 12 nm in diameter at 25° C. 
It is seen from FIG. 6(a) that when the size of the nanopar-
ticles increases from 6 to 12 nm, the value ofR2 is doubled. 
This is consistent with the experimental evidence showing 
that stable clustering of magnetic nanoparticles can generate 
35 particles for the Cy3-MION +Cy5-MION, indicating an effect 
of the interaction of magnetic particles. The hybridized 
MION's show an effective concentration 34% higher than 
that predicted value based on the single MION particle con-
centration. These results indicate that is possible to distin-
40 guish between scattered and clustered multifunctional mag-
netic nanoparticle probes of the present invention, using both 
a FRET-based assay and magnetic resonance imaging. Opti-
mization of the design will focus on oligonucleotide struc-
ture. Specifically, for the design proposed in FIG. 6b, the size a measurable change in the relaxation effects. For example, 
when several caged superparamagnetic particles (3 nm) were 
clustered due to binding between attached oligonucleotide 
probes and complementary targets in solution, there was a 
two-fold increase in the R2 of water (Josephson et al., 2001). 
Similarly, self-hybridization of two complementary oligo-
nucleotides with conjugated magnetic nanoparticles reduced 50 
the relaxation time T 2 by a factor of 2 (from 61 ms to 3 2 ms) 
(Perez et al., 2002.). 
45 of the gap between the probe sections on the target will be 
varied to determine the optimal length necessary for maxi-
mum contrast without compromising hybridization of the 
probes to the target mRNA. 
Example 5 
Use of Magnetic Nanoparticle Probes to Detect Viral Infec-
tion or Traumatic Injury in Rats 
The first model involves a viral infection (influenza virus 
A) in rats. Virus is injected into one of animal's hind leg and 
allowed to develop for 24 hours before imaging. The nano-
probes, designed to target the eotaxin mRNA, are then be 
injected. The imaging studies will compare the two hind legs 
When two oligonucleotide probes are designed such that 
they hybridize to the same target mRNA in a head-to-head 
fashion, as illustrated in FIG. 6(b ), or hybridize to each other, 55 
as illustrated in FIG. 7, the two conjugated magnetic nano-
particles may act together, generating an 'effective' particle 
that is about twice as large as the individual nanoparticles, and 
leading to dramatically enhanced effect on the relaxivities R2 
and/or R1 . Such an effect is readily measurable with MRI. 60 and also assess the heterogeneity of the infected leg. Contrast 
will be quantitatively assessed by comparing image intensity 
of the infected leg with the control leg. 
To evaluate the difference between the MRI signal gener-
ated by the hybridized complex as compared to the individual 
oligonucleotide samples T2 relaxation time was measured for 
the same samples used for the optical detection using FRET. 
In this assay, the total MION particle concentration in the 
Cy3-MION Cy5-MION sample was the average of the MION 
concentration in the individual samples (Cy3-MION, Cy5-
The second model is a brain injury model of rats induced by 
inertial acceleration. It has been shown that the mRNA 
65 expression of cytochrome c oxidase II (COII), a mitochon-
drial encoded subunit of complex IV, is upregulated following 
traumatic brain injury (TBI). The severity of the injury will be 
US 7,459,145 B2 
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made very low so that no edema will be present and little 
contrast is seen on conventional MRI. The animal will be 
imaged before the injury, after the injury but without the 
nanoprobes, and afterthe injury with nanoprobes. Contrast to 
noise ratios between the injured area and the surrounding 
tissue will be calculated. 
Previous in vivo studies in the liver demonstrated robust 
contrast at a spatial resolution of 1 mm. That study was 
performed at 0.47 T and using a human head coil. For the 
proposed studies, a specialized coil will be used that is much 
smaller than the head coil used in the liver study. The studies 
will be performed at 3 T. With the increase in field strength 
and coil sensitivity, which will increase the signal-to-noise 
ratio and the relaxation effect of the magnetic nanoparticles, 
we expect a substantial increase in detection sensitivity, 
allowing us to achieve a resolution of 0.1 mm in mice. This 
resolution should be sufficient for studying infected areas 
with sufficient spatial resolution. 
Example 6 
Use of Multifunctional Magnetic Nanoparticle Probes to 
Detect Cancer 
It is well established that cancer cells develop due to 
genetic alterations in oncogenes and tumor suppressor genes 
and abnormalities in gene expression that provide growth 
advantage and metastatic potential to the cells. A critical step 
in diagnosing and treating cancer in its early stages is to detect 
cancer cells based on the genetic alterations. 
A novel way of achieving early detection of cancer is to 
identify cancer cells through detection of mRNA transcripts 
that exist in cancer cells but not in normal cells. The multi-
functional magnetic nanoparticle probes of the present inven-
tion could be utilized for the early detection of cancer cells, 
using optical imaging or magnetic resonance imaging. 
EXAMPLE 7 
Specific mRNA Detection in Living Cells Using Peptide-
linked Nucleic Acid Probes 
To demonstrate the rapid and sensitive detection of mRNA 
in living cells, we developed peptide-linked nucleic acid 
probes that possess self-delivery, targeting and reporting 
functions. We conjugated the TAT peptide to nucleic acid 
32 
tide-based delivery did not interfere with either specific tar-
geting by or hybridization-induced fluorescence of the 
probes. 
We could therefore detect human GAPDH and Survivin 
mRNAs in living cells fluorescently, revealing intriguing 
intracellular localization patterns of mRNA. 
We designed and synthesized peptide-linked nucleic acid 
probes targeting thehuman GAPDH (glyceraldehyde 3-phos-
10 phate dehydrogenase) and survivin mRNAs, as well as 
nucleic acid probes with a 'random' probe sequence. The 
specific design of these nucleic acid probes, and the sequence 
of the 11 amino-acid TAT-1 peptide used in the study are 
shown in Table 2. The GAPDH beacon is comprised of a 
15 19-base pro be domain targeting the Exon 6 region of GAPD H 
gene flanked by complementary 5-base sequences that 
hybridize to form the stem. The survivin beacon has a 16-base 
target sequence with a similar design of the stem. The 'ran-
dom' beacon was designed as a negative control, with a 
20 17-base probe sequence that does not have any match in the 
entire human genome. 
Three conjugation strategies were developed in attaching 
the delivery peptide to nucleic acid probes, as illustrated in 
FIG. 12 In the first approach (FIG.12A), peptides were linked 
25 to a nucleic acid probe through a streptavidin-biotin bridge by 
introducing a modified oligonucleotide, biotin-dT, to the 
quencher arm of the stem through a carbon- 12 spacer. The 
peptide-linked nucleic acid probe consisted the biotin-modi-
fied nucleic acid probe, a streptavidin molecule, and biotin-
modified TAT-1 peptides. Since each streptavidin molecule 
30 has four biotin-binding sites, we were able to link biotin-
modified nucleic acid probes and delivery peptides on the 
same streptavidin molecule. The stoichiometry was con-
trolled so that the probability of having more than one nucleic 
acid probes linked to the same streptavidin is small. In the 
35 second design (FIG. 12B), we placed a thiol group to the 
quencher-arm of the nucleic acid probe stem through a carbon 
linker; the thiol group then reacted with a maleimide group 
added to the C terminus of the peptide to form a thiol-male-
imide linkage (FIG. 12B). Both the streptavidin-biotin bridge 
40 and the thiol-maleimide linkage are stable in the cell cyto-
plasm. As the third approach, we functionalized the TAT-1 
peptide by adding a cysteine residue at the C terminus which 
forms a disulfide bridge with the thiol-modifled nucleic acid 
probe as shown in FIG. 12C. This cleavable design was based 
45 
on the rationale that the reducing environment of the cyto-
plasm will cleave the disulfide bond once the construct enters 
the cell, thereby separating peptide from probe. 
TABLE 3 
Design of peptide-linked molecular beacons 
Peptide 
TAT (N terminus)TyrGlyArgLysLysArgArgGlnArgArgArg(C terminus) (SEQ ID N0,29) 
Modified Molecular Beacons 
GAPDH 5'-Cy3-CGACGGAGTCCTTCCACGATACCACG/thiol-d!/CG-BHQ2-3' (SEQ ID NO 30) 
Survivin5'-Cy3-CGACGGAGAAAGGGCTGCCACG/thiol-d!/CG-BHQ2-3' (SEQ ID NO 31) 
Random 5'-Cy3-CGACGCGACAAGCGCACCGATACG/thiol-d!/CG-BHQ2-3' (SEQ ID NO 32) 
probes using three different linkages and demonstrated that, 
at relatively low (~200 nM) concentrations, these nucleic 
acid probe constructs were internalized into living cells 
within 30 minutes with nearly 100% efficiency. Further, pep-
Primary human dermal fibroblast (HDF) cells (Cambrex, 
65 N.J.) anda pancreatic cancercell lineMiaPaca-2 (ATCC, VA) 
were used for this study. These cells were cultured in an 
8-well Nalge Nurre culture plate with a glass coverslip bottom 
US 7,459,145 B2 
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in their respective cell culture media for 24 hours prior to 
experiments. Delivery assays were performed by incubating 
cells at 37° C. with the media containing peptide-linked 
nucleic acid probes. For nucleic acid probes targeting 
GAPDH, peptide-linked nucleic acid probes with three dif- 5 
ferent concentrations (0.25 µM, 0.5 µM and 1.0 µM) were 
incubated with HDF cells for 30, 60 and 90 minutes. For 
nucleic acid probes targeting survivin, 0.5 µM of peptide-
linked nucleic acid probes were incubated with HDF and 
MiaPaca-2 cells for 30 minutes. For all assays, the cells were 10 
washed twice with PBS to remove the incubation medium and 
34 
To demonstrate the ability of nucleic acid probes to deter-
mine gene transcription levels, we observed expression of 
Survivin mRNA in live HDF and MiaPaca-2 cells. We and 
others have demonstrated that the Survivin expression level is 
very low in HDF cells, whereas in MiaPaCa-2 cells the level 
is relatively high. After 60 minutes of incubation with pep-
tide-linked nucleic acid probes, the fluorescence signal in 
MiaPaca-2 cells was quite high, as shown in FIG. 13A, but in 
HDF cells, only very low fluorescence signal can be observed 
(FIG. 13C). In addition, Survivin mRNAs shown an intrigu-
ing localization pattern, i.e., the SurvivinmRNAmolecules in 
MiaPaCa-2 cells seemed to be concentrated near one side of 
the cell nucleus (FIG. 13B). Although with very low expres-
sion level, Survivin mRNA localized in HDF in a similar 
placed in fresh medium for fluorescence imaging, which was 
carried out using a confocal microscope (Axiovert LSM-100, 
Zeiss). 15 fashion (FIG. 13C). Previous research suggested that the 
expression level and localization of Survivin may be an 
important indicator for cancer progression or prognosis. 
To demonstrate the self-delivery and mRNA targeting 
functions of peptide-linked nucleic acid probes, we first 
detected mRNA of a housekeeping gene human GAPDH in 
normal human dermal fibroblast (HDF) cells. After just 30 
minutes ofincubation with TAT-peptide conjugated GAPDH- 20 
targeting nucleic acid probes, we observed clear and localized 
fluorescence signal in HDF cells as a result of nucleic acid 
probe-target mRNA hybridization for all three conjugation 
schemes, i.e., thiol-maleimide, disulfide bridge and strepta-
vidin-biotin (data not shown). In contrast, peptide-linked ran-
dom-sequence nucleic acid probes with streptavidin-biotin 
conjugation gave essentially no signal 30 minutes after deliv-
ery (data not shown). Similar results were obtained using 
random-sequence nucleic acid probes with thiol-maleimide 
and disulfide linkages for peptide (data not shown). This 
demonstrates that peptide-linked nucleic acid probes 
remained highly specific in living cells after internalization. 
Further, we found that GAPDH mRNAs displayed a very 
intriguing filament-like localization pattern in HDF cells, 
with a clear tendency of surrounding the cell nucleus and 
following the cell morphology (data not shown). Interest-
ingly, nucleic acid probes with the cleavable (thiol-cysteine 
disulfide bridge) design seemed to give better localization 
patterns than those with the thiol-maleimide linkage, and the 
latter seemed to perform better than nucleic acid probes with 40 
the streptavidin-biotin linkage. Cleavage of the delivery pep-
tide from the construct may have provided nucleic acid 
probes a better access to target mRNA molecules, although 
more studies of this phenomenon are required to validate this 
assumption. It is likely that a nucleic acid probe with a rela- 45 
tively bulky streptavidin molecule is less able to penetrate 
into the secondary structure of the GAPDH mRNA, thus 
reducing its ability to seek out its targets. Almost all the HDF 
cells exposed to GAPDH peptide-linked nucleic acid probes 
showed strong fluorescence signal, implying a near 100% 50 
delivery efficiency (data not shown). 
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<160> NUMBER OF SEQ ID NOS, 32 
<210> SEQ ID NO 1 
<211> LENGTH, 11 
<212 > TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
50 mentation, many equivalents to the specific embodiments of 
the invention described herein. Such equivalents are intended 
to be encompassed by the following claims. 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
37 
<400> SEQUENCE, 1 
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1 5 10 
<210> SEQ ID NO 2 
<211> LENGTH, 34 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 7,459,145 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 2 
Asp Ala Ala Thr Ala Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr 
1 5 10 15 
Glu Arg Pro Arg Ala Pro Ala Arg Ser Ala Ser Arg Pro Arg Arg Pro 
20 25 30 
Val Glu 
<210> SEQ ID NO 3 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 3 
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1 5 10 15 
<210> SEQ ID NO 4 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 4 
Arg Arg Trp Arg Arg Trp Trp Arg Arg Trp Trp Arg Arg Trp Arg Arg 
1 5 10 15 
<210> SEQ ID NO 5 
<211> LENGTH, 12 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 5 
Thr Pro Pro Lys Lys Lys Arg Lys Val Glu Asp Pro 
1 5 10 
<210> SEQ ID NO 6 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 
Cys Trp Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1 5 10 15 
38 
Lys Lys Lys Lys 
20 
<210> SEQ ID NO 7 
<211> LENGTH, 40 
<212> TYPE, PRT 
39 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 7,459,145 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 7 
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1 5 10 15 
Lys Lys Trp Cys Cys Trp Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
20 25 30 
Lys Lys Lys Lys Lys Lys Lys Lys 
35 40 
<210> SEQ ID NO 8 
<211> LENGTH, 27 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 8 
Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu 
1 5 10 15 
Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 
20 25 
<210> SEQ ID NO 9 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 9 
Gly Leu Phe Glu Ala Leu Glu Glu Leu Trp Glu Ala Lys 
1 5 10 
<210> SEQ ID NO 10 
<211> LENGTH, 46 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 10 
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1 5 10 15 
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Ala Lys Lys Lys Lys Lys 
20 25 30 
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Arg Gly Asp 
35 40 45 
<210> SEQ ID NO 11 
<211> LENGTH, 25 
<212> TYPE, PRT 
40 
41 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 7,459,145 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 11 
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1 5 10 15 
Gly Gly Cys Met Phe Gly Cys Gly Gly 
20 25 
<210> SEQ ID NO 12 
<211> LENGTH, 31 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 12 
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1 5 10 15 
Ile Cys Arg Arg Ala Arg Gly Asp Asn Pro Asp Asp Arg Cys Thr 
20 25 30 
<210> SEQ ID NO 13 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<220> FEATURE, 
<221> NAME/KEY, MOD_RES 
<222> LOCATION, (17) 
<223> OTHER INFORMATION, Beta-Ala 
<220> FEATURE, 
<221> NAME/KEY, MOD_RES 
<222> LOCATION, (19) 
<223> OTHER INFORMATION, Lys coupled to biotin (D-biocytin) 
<220> FEATURE, 
<221> NAME/KEY, MOD_RES 
<222> LOCATION, (20) 
<223> OTHER INFORMATION, Beta-Ala 
<400> SEQUENCE, 13 
Lys Lys Trp Lys Met Arg Arg Asn Gln Phe Trp Val Lys Val Gln Arg 
1 5 10 15 
Ala Lys Xaa Ala 
20 
<210> SEQ ID NO 14 
<211> LENGTH, 30 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 14 
Val Ala Tyr Ile Ser Arg Gly Gly Val Ser Thr Tyr Tyr Ser Asp Thr 
1 5 10 15 
Val Lys Gly Arg Phe Thr Arg Gln Lys Tyr Asn Lys Arg Ala 
20 25 30 
<210> SEQ ID NO 15 
<211> LENGTH, 32 
42 
43 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 7,459,145 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 15 
Ile Gly Arg Ile Asp Pro Ala Asn Gly Lys Thr Lys Tyr Ala Pro Lys 
1 5 10 15 
Phe Gln Asp Lys Ala Thr Arg Ser Asn Tyr Tyr Gly Asn Ser Pro Ser 
20 25 30 
<210> SEQ ID NO 16 
<211> LENGTH, 12 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 16 
Pro Leu Ala Glu Ile Asp Gly Ile Glu Leu Thr Tyr 
1 5 10 
<210> SEQ ID NO 17 
<211> LENGTH, 30 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 17 
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1 5 10 15 
Gly Gly Pro Leu Ala Glu Ile Asp Gly Ile Glu Leu Gly Ala 
20 25 30 
<210> SEQ ID NO 18 
<211> LENGTH, 30 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 18 
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1 5 10 15 
Gly Gly Pro Leu Ala Glu Ile Asp Gly Ile Glu Leu Cys Ala 
20 25 30 
<210> SEQ ID NO 19 
<211> LENGTH, 28 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 19 
Gly Ala Leu Phe Leu Gly Phe Leu Gly Gly Ala Ala Gly Ser Thr Met 
1 5 10 15 
Gly Ala Trp Ser Gln Pro Lys Ser Lys Arg Lys Val 
20 25 
44 
<210> SEQ ID NO 20 
<211> LENGTH, 28 
<212> TYPE, PRT 
45 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 7,459,145 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 20 
Trp Glu Ala Lys Leu Ala Lys Ala Leu Ala Lys Ala Leu Ala Lys His 
1 5 10 15 
Leu Ala Lys Ala Leu Ala Lys Ala Leu Lys Ala Cys 
20 25 
<210> SEQ ID NO 21 
<211> LENGTH, 24 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 21 
Leu Ala Arg Leu Leu Ala Arg Leu Leu Ala Arg Leu Leu Ala Arg Leu 
1 5 10 15 
Leu Ala Arg Leu Leu Ala Arg Leu 
20 
<210> SEQ ID NO 22 
<211> LENGTH, 18 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 22 
Lys Leu Leu Lys Leu Leu Leu Lys Leu Trp Leu Lys Leu Leu Lys Leu 
1 5 10 15 
Leu Leu 
<210> SEQ ID NO 23 
<211> LENGTH, 11 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 23 
Lys Lys Lys Lys Lys Lys Lys Lys Gly Gly Cys 
1 5 10 
<210> SEQ ID NO 24 
<211> LENGTH, 11 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 24 
Lys Trp Lys Lys Lys Trp Lys Lys Gly Cys Cys 
1 5 10 
46 
<210> SEQ ID NO 25 
<211> LENGTH, 11 
<212> TYPE, PRT 
47 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 7,459,145 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 25 
Arg Trp Arg Arg Arg Trp Arg Arg Gly Gly Cys 
1 5 10 
<210> SEQ ID NO 26 
<211> LENGTH, 42 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 26 
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1 5 10 15 
Lys Lys Lys Lys Lys Lys Lys Gly Gly Lys Lys Lys Lys Lys Pro Asp 
20 25 30 
Glu Val Lys Arg Lys Lys Lys Pro Pro Thr 
35 40 
<210> SEQ ID NO 27 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetc 
probe 
<400> SEQUENCE, 27 
gagtccttcc acgatactac gatccacatt 
<210> SEQ ID NO 28 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetc 
probe 
<400> SEQUENCE, 28 
aatgtggatc gtagtatcgt cgaaggactc 
<210> SEQ ID NO 29 
<211> LENGTH, 11 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 29 
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1 5 10 
<210> SEQ ID NO 30 
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
48 
30 
30 
US 7,459,145 B2 
49 50 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 30 
cgacggagtc cttccacgat accacg 
<210> SEQ ID NO 31 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
26 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 31 
cgacggagaa agggctgcca cg 
<210> SEQ ID NO 32 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
22 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 32 
cgacgcgaca agcgcaccga tacg 
We claim: 
1. A nanoparticle probe compos1t10n for facilitating 
molecular imaging or monitoring, comprising: 
24 
the P3a peptide (SEQ ID NO: 14), the P9.3 peptide (SEQ ID 
NO: 15), the Plae peptide (SEQ ID NO: 16), the Kplae peptide 
(SEQ ID NO: 17), the cKplae peptide (SEQ ID NO: 18), the 
a detectable moiety comprising a magnetic nanoparticle 
having a biocompatible coating thereon; 
a targeting probe attached to the biocompatible coating, 
wherein the targeting probe is selected from the group 
consisting of a nucleic acid pro be, an antibody, an anti-
body fragment, and an aptamer; and 
35 MGP peptide (SEQ ID NO: 19), the HA2 peptide (SEQ ID 
N0:20), the LARL46 peptide (SEQ ID N0:21 ), the Hel-11-7 
peptide (SEQ ID N0:22), the KK peptide (SEQ ID N0:23), 
the KWK peptide (SEQ ID N0:24), the RWR peptide (SEQ 
ID N0:25), and the Loligomer peptide (SEQ ID N0:26). 
an intracellular delivery ligand attached to the biocompat-
ible coating. 
2. The composition of claim 1, wherein the targeting probe 
is a nucleic acid probe. 
40 
3. The composition of claim 2, wherein the nucleic acid 45 
pro be hybridizes to a nucleic acid target sequence on a subject 
nucleic acid and forms a stem-loop structure when not bound 
to the nucleic acid target sequence. 
4. The composition of claim 2, wherein the nucleic acid 
probe comprises a modification of the nucleic acid backbone 50 
for the increased stability of the nucleic acid as compared to 
a naturally occurring nucleic acid. 
5. The composition of claim 1, wherein the targeting probe 
is an antibody or fragment thereof. 
6. The composition of claim 1, wherein the targeting probe 55 
is an aptamer. 
7. The composition of claim 1, wherein the delivery ligand 
comprises a protein transduction peptide selected from the 
group consisting ofHIV-1 TAT, HSVVP22, andANTP. 
8. The composition of claim 1, wherein the intracellular 60 
delivery ligand is selected from the group consisting of the 
W /R peptide (SEQ ID N0:4 ), NLS * peptide (SEQ ID NO: 5), 
theAlkCWK18 peptide (SEQ ID N0:6), DiCWK18 peptide 
(SEQ ID N0:7), the transportan peptide (SEQ ID NO:S), the 
DipaLytic peptide (SEQ ID N0:9), the K16RGD peptide 65 
(SEQ ID NO:lO), the Pl peptide (SEQ ID NO:ll), the P2 
peptide (SEQ ID N0:12), the P3 peptide (SEQ ID N0:13), 
9. The composition of claim 1, wherein the intracellular 
delivery ligand facilitates receptor-mediated endocytosis of 
the composition. 
10. The composition of claim 1, wherein the intracellular 
delivery ligand facilitates entry into a cell by permeabilizing 
the cell membrane. 
11. The composition of claim 1, wherein the magnetic 
nanoparticle comprises a metal detectable by use of an MRI 
instrument that is selected from the group consisting of 
selected from the group consisting of iron, cobalt, zinc, cad-
mium, nickel, gadolinium, chromium, copper, manganese, 
terbium, europium, gold, silver, platinum, and alloys thereof. 
12. The composition of claim 11, wherein the magnetic 
nanoparticle is selected from the group consisting of monoc-
rystalline iron oxide nanoparticle (MION), chelate of gado-
linium, and superparamagnetic iron oxide (SPIO). 
13. The composition of claim 11, wherein the magnetic 
nanoparticle is monocrystalline iron oxide nanoparticle 
(MION). 
14. The composition of claim 11, wherein the magnetic 
nanoparticle is a free metal ion, a metal oxide, a chelate, or an 
insoluble metal compound. 
15. The composition of claim 11, wherein the magnetic 
nanoparticle is selected from the group consisting ofFe30 4 , 
Fe2 0 4 , FexPty, CoxPty, MnFexOy, CoFexOy, NiFexOy, 
CuFexOy, ZnFexOy, and CdFexOy, wherein x and y vary 
between 1 and 6, depending on the method of synthesis. 
US 7,459,145 B2 
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16. The composition of claim 11, wherein the magnetic 
nanoparticle further comprises a metal coating selected from 
the group consisting of gold, silver, iron, cobalt, zinc, cad-
mium, nickel, gadolinium, chromium, copper, and manga-
nese, and an alloy thereof. 
17. The composition of claim 1, wherein the biocompatible 
coating is selected from the group consisting of a surfactant 
based coating, a starch based coating, a dextran based coat-
ing, a silica based coating, a layer by layer coating, a phos-
pholipid-polyethylene glycol coating, a polymer coating, a 
mesoporous particle coating, a microporous particle coating, 
a lipid based coating, and a dendrimer based coating. 
18. The composition of claim 1, wherein the biocompatible 
coating is a phospholipid-polyethylene glycol coating. 
19. The composition of claim 1, wherein the composition 
further comprises a second delivery ligand that is attached to 
the biocompatible coating and that interacts with a molecule 
located on the outer surface of a particular type of cell or 
tissue. 
52 
targeting probe attached to the biocompatible coating; 
and a delivery ligand attached to the biocompatible coat-
ing; and 
a fourth magnetic nanoparticle probe composition com-
prising a detectable moiety comprising a magnetic nano-
particle having a biocompatible coating thereon; a 
fourth targeting probe attached to the biocompatible 
coating; and a delivery ligand attached to the biocom-
patible coating; 
10 wherein the third nucleic acid probe hybridizes to a third 
nucleic acid target sequence on the subject nucleic acid and 
the fourth nucleic acid probe hybridizes with a fourth nucleic 
acid target sequence on the subject nucleic acid; and wherein 
the third nucleic acid target sequence and the fourth nucleic 
15 acid target sequence are separated by a number of nucleotides 
on the subject nucleic acid such that an effect on water relax-
ation from interaction between the third and fourth magnetic 
nanoparticles can be detected to determine hybridization of 
both the third and the fourth nucleic acid probes. 
20. The composition of claim 1, further comprising a sec- 20 
ond detectable moiety attached to the biocompatible coating, 
wherein the second detectable moiety is selected from the 
group consisting of a resonance energy transfer donor moi-
ety; a resonance energy transfer acceptor moiety; a radioiso-
tope; a fluorescent dye; an organic bead, a chelator, or a 25 
magnetic nanoparticle with fluorescent or luminescent char-
acteristics; and an inorganic bead with fluorescent or lumi-
nescent characteristics. 
24. The composition of claim 22, wherein the composition 
further comprises additional magnetic nanoparticle probe 
pairs. 
25. The composition of claim 22, wherein the first nucleic 
acid pro be, the second nucleic acid pro be, or both nucleic acid 
probes hybridize to a nucleic acid target sequence on a subject 
nucleic acid and form a stem-loop structure when not bound 
to the nucleic acid target sequence. 
26. The composition of claim 22, wherein the first nucleic 
acid pro be, the second nucleic acid pro be, or both nucleic acid 
probes comprise a modification of the nucleic acid backbone 
for the increased stability of the nucleic acid as compared to 
21. A composition for facilitating signal transduction in 
molecular imaging or monitoring, comprising: 30 
a first magnetic nanoparticle probe composition compris-
ing a detectable moiety comprising a magnetic nanopar-
ticle having a biocompatible coating thereon; a first tar-
geting probe attached to the biocompatible coating; and 
35 
a delivery ligand attached to the biocompatible coating; 
and 
a naturally occurring nucleic acid. 
27. The composition of claim 21, wherein the first and the 
second targeting probes are polypeptide probes; wherein the 
first polypeptide probe binds to a first target sequence on a 
subject polypeptide and the second polypeptide probe binds 
with a second target sequence on a subject polypeptide; and 
wherein the first target sequence and the second target 
sequence are separated by a distance such that an effect on 
a second magnetic nanoparticle probe composition com-
prising a detectable moiety comprising a magnetic nano-
particle having a biocompatible coating thereon; a sec-
ond targeting probe attached to the biocompatible 
coating; and a delivery ligand attached to the biocom-
patible coating; 
wherein the first targeting probe binds to a first target and the 
second targeting probe binds with a second target; and 
wherein an effect on water relaxation from interaction 
between the first and second magnetic nanoparticles is 
detected to determine binding of both the first and the second 
targeting probes to the first and the second target, and wherein 
the first magnetic nanoparticle probe composition is different 
than the second magnetic nanoparticle probe composition. 
22. The composition of claim 21, wherein the first targeting 
probe and the second targeting probe are nucleic acid probes; 
wherein the first nucleic acid probe hybridizes to a first 
nucleic acid target sequence on a subject nucleic acid and the 
second nucleic acid probe hybridizes with a second nucleic 
acid target sequence on the subject nucleic acid; and wherein 
the first nucleic acid target sequence and the second nucleic 
acid target sequence are separated by a number of nucleotides 
on the subject nucleic acid such that an effect on water relax-
ation from interaction between the first and second magnetic 
nanoparticles can be detected to determine hybridization of 
both the first and the second nucleic acid probes. 
23. The composition of claim 22, further comprising 
40 water relaxation from interaction between the first and second 
magnetic nanoparticles is detected to determine binding of 
both the first and the second polypeptide probes. 
28. The composition of claim 27, wherein the first and the 
second target sequences are located on a single subject 
45 polypeptide. 
29. The composition of claim 27, wherein the first target 
sequence is located on a first subject polypeptide and the 
second target sequence is located on a second subject 
polypeptide; and wherein effect on water relaxation from 
50 interaction between the first and second magnetic nanopar-
ricles is detected to determine the interaction of the first 
subject polypeptide and the second subject polypeptide. 
30. The composition of claim 27, wherein the first targeting 
pro be, the second targeting probe, or both targeting pro bes are 
55 antibodies or fragments thereof. 
31. The composition of claim 21, wherein the first or the 
second magnetic nanoparticle probe composition or both 
comprise two or more targeting probes. 
32. The composition of claim 21, wherein the intracellular 
60 delivery ligand comprises a cell penetrating peptide selected 
from the group consisting of HIV-1 TAT, HSY VP22, and 
ANTP. 
a third magnetic nanoparticle probe composition compris- 65 
ing a detectable moiety comprising a magnetic nanopar-
ticle having a biocompatible coating thereon; a third 
33. The composition of claim 21, wherein the intracellular 
delivery ligand is selected from the group consisting of the 
W/R peptide (SEQ ID N0:4), the NLS* peptide (SEQ ID 
N0:5), theAlkCWK18 peptide (SEQ ID N0:6), DiCWK18 
peptide (SEQ ID N0:7), the transportan peptide (SEQ ID 
US 7,459,145 B2 
53 
N0:8), the DipaLytic peptide (SEQ ID N0:9), the Kl6RGD 
peptide (SEQ ID NO:lO), the Pl peptide (SEQ ID NO:ll), 
the P2 peptide (SEQ ID NO:l2), the P3 peptide (SEQ ID 
N0:13), the P3a peptide (SEQ ID NO:l4), the P9.3 peptide 
(SEQ ID NO: 15), the Plae peptide (SEQ ID NO: 16), the 5 
Kplae peptide (SEQ ID NO: 17), the cKplae peptide (SEQ ID 
NO:l8), theMGPpeptide (SEQ ID NO:l9), theHA2 peptide 
(SEQ ID N0:20), the LARL46 peptide (SEQ ID N0:21 ), the 
Hel-11-7 peptide (SEQ ID N0:22), the KK peptide (SEQ ID 
N0:23), the KWK peptide (SEQ ID N0:24), the RWR pep- 10 
tide (SEQ ID N0:25), and the Loligomer peptide (SEQ ID 
N0:26). 
34. The composition of claim 21, wherein the magnetic 
nanoparticle comprises a metal detectable by use of an MRI 
instrument that is selected from the group consisting of 15 
selected from the group consisting of iron, cobalt, zinc, cad-
mium, nickel, gadolinium, chromium, copper, manganese, 
terbium, europium, gold, silver, platinum, and alloys thereof. 
35. The composition of claim 34, wherein the magnetic 
nanoparticle is monocrystalline iron oxide nanoparticle 20 
(MION). 
36. The composition of claim 34, wherein the magnetic 
nanoparticle is a free metal ion, a metal oxide, a chelate, or an 
insoluble metal compound. 
37. The composition of claim 34, wherein the magnetic 25 
nanoparticle is selected from the group consisting ofFe30 4 , 
Fe20 4 , FexPtY, CoxPtY, MnFexOy, CoFexOy, NiFexOy, 
CuFexOy, ZnFexOy, and CdFexOy, wherein x and y vary 
between 1 and 6 depending on the method of synthesis. 
38. The composition of claim 34, wherein the magnetic 30 
nanoparticle further comprises a metal coating selected from 
the group consisting of gold, silver, iron, cobalt, zinc, cad-
mium, nickel, gadolinium, chromium, copper, manganese, 
and an alloy thereof. 
39. The composition of claim 21, wherein the biocompat- 35 
ible coating is selected from the group consisting of a surfac-
tant based coating, a starch based coating, a dextran based 
coating, a silica based coating, a layer by layer coating, a 
phospholipid-polyethylene glycol coating, a polymer coat-
ing, a mesoporous particle coating, a microporous particle 40 
coating, a lipid based coating, and a dendrimer based coating. 
40. The composition of claim 21, wherein the biocompat-
ible coating is a phospholipid-polyethylene glycol coating. 
41. The composition of claim 21, wherein the first mag-
netic nanoparticle probe composition, the second magnetic 45 
nanoparticle probe composition, or both further comprise a 
second delivery ligand that is attached to the biocompatible 
coating and that interacts with a molecule located on the outer 
surface of a particular type of cell or tissue. 
42. The composition of claim 21, wherein the first mag- 50 
netic nanoparticle probe composition, the second magnetic 
nanoparticle probe composition, or both further comprise a 
second detectable moiety attached to the biocompatible coat-
ing, wherein the detectable moiety is selected from the group 
consisting of a resonance energy transfer donor or acceptor 55 
moiety, a fluorescent dye, an organic bead with fluorescent or 
luminescent characteristics, and an inorganic bead with fluo-
rescent or luminescent characteristics. 
43. The composition of claim 21, wherein the first mag-
netic nanoparticle probe composition, the second magnetic 60 
nanoparticle probe composition, or both further comprise a 
therapeutic molecule attached to the biocompatible coating or 
to the magnetic nanoparticle. 
44. A composition for facilitating molecular imaging, com-
prising two or more magnetic nanoparticle probe composi- 65 
tions within a vesicle, wherein each magnetic nanoparticle 
probe composition comprises at least one targeting probe and 
54 
a detectable moiety attached thereto, wherein the detectable 
moiety comprises a magnetic nanoparticle having a biocom-
patible coating thereon, and wherein the vesicle comprises a 
biocompatible membrane having at least one delivery ligand 
on its outer surface. 
45. A method for producing a magnetic nanoparticle pro be 
composition for facilitating molecular imaging, comprising: 
combining a magnetic nanoparticle with a biocompatible 
coating; 
adding an intracellular delivery ligand; and 
adding a targeting probe, wherein the targeting probe is 
selected from the group consisting of a nucleic acid 
probe, an antibody, an antibody fragment, and an 
aptamer. 
46. The method of claim 45, wherein the intracellular 
delivery ligand is selected from the group consisting of the 
HIY-1 TAT peptide (SEQ ID NO: 1 ), the HSY YP22 peptide 
(SEQ ID N0:2), theANTP peptide (SEQ ID N0:3), the W/R 
peptide (SEQ ID N0:4), the NLS* peptide (SEQ ID N0:5), 
the AlkCWKl 8 peptide (SEQ ID N0:6), DiCWKl 8 peptide 
(SEQ ID N0:7), the transportan peptide (SEQ ID NO: 8), the 
DipaLytic peptide (SEQ ID N0:9), the Kl6RGD peptide 
(SEQ ID NO:lO), the Pl peptide (SEQ ID NO:ll), the P2 
peptide (SEQ ID NO:l2), the P3 peptide (SEQ ID NO:l3), 
the P3a peptide (SEQ ID NO: 14), the P9.3 peptide (SEQ ID 
NO: 15), the Plae peptide (SEQ ID NO: 16), the Kplae peptide 
(SEQ ID NO: 17), the cKplae peptide (SEQ ID NO: 18), the 
MGP peptide (SEQ ID NO: 19), the HA2 peptide (SEQ ID 
N0:20), the LARL46 peptide (SEQ ID N0:21 ), the Hel-11-7 
peptide (SEQ ID N0:22), the KK peptide (SEQ ID N0:23), 
the KWK peptide (SEQ ID N0:24), the RWR peptide (SEQ 
ID N0:25), and the Loligomer peptide (SEQ ID N0:26). 
47. The method of claim 45, wherein the magnetic nano-
particle comprises a metal detectable by an MRI instrument 
that is selected from the group consisting of selected from the 
group consisting ofiron, cobalt, zinc, cadmium, nickel, gado-
linium, chromium, copper, and manganese. 
48. The method of claim 45, wherein the magnetic nano-
particle is monocrystalline iron oxide nanoparticle (MION). 
49. The method of claim 45, wherein the biocompatible 
coating is selected from the group consisting of a surfactant 
based coating, a starch based coating, a dextran based coat-
ing, a silica based coating, a layer by layer coating, a phos-
pholipid-polyethylene glycol coating, a polymer coating, a 
mesoporous particle coating, a microporous particle coating, 
a lipid based coating, and a dendrimer based coating. 
50. The method of claim 45, wherein the biocompatible 
coating is a phospholipid-polyethylene glycol coating. 
51. The method of claim 45, further comprising the step of 
adding a second delivery ligand to the biocompatible coating 
that interacts with a molecule located on the outer surface of 
a particular type of cell or tissue. 
52. The method of claim 45, further comprising the step of 
adding a therapeutic molecule to the biocompatible coating. 
53. A nanoparticle probe composition for facilitating 
molecular imaging or monitoring, comprising: 
a detectable moiety comprising a magnetic nanoparticle 
having a biocompatible coating thereon; 
a targeting probe attached to the biocompatible coating; 
and 
an intracellular delivery ligand attached to the biocompat-
ible coating, 
wherein the intracellular delivery ligand is selected from the 
group consisting of the HSY YP22 peptide (SEQ ID N0:2), 
the ANTP peptide (SEQ ID N0:3 ), the W /R peptide (SEQ ID 
N0:4), the NLS* peptide (SEQ ID N0:5), the AlkCWKlS 
peptide (SEQ ID N0:6), the DiCWK18 peptide (SEQ ID 
US 7,459,145 B2 
55 
N0:7), thetransportan peptide (SEQ ID N0:8), the DipaLytic 
peptide (SEQ ID N0:9), the KI6RGD peptide (SEQ ID 
NO:lO), the Pl peptide(SEQID 10:11), theP2 peptide (SEQ 
ID N0:12), the P3 peptide (SEQ ID N0:13), the P3a peptide 
(SEQ ID NO: 14 ), the P9 .3 peptide (SEQ ID NO: 15), the Plac s 
peptide (SEQ ID NO: 16), the Kplae peptide (SEQ ID 
NQ: 17), the cKplae peptide (SEQ ID NO: 18), the MGP 
peptide (SEQ ID NO: 19), the HA2 peptide (SEQ ID N0:20), 
the LARL46 peptide (SEQ ID N0:21), the Hel-11-7 peptide 
(SEQ ID N0:22), the KK peptide (SEQ ID N0:23), the KWK 10 
peptide (SEQ ID N0:24 ), the RWR peptide (SEQ ID N0:2 5), 
and the Loligomer peptide (SEQ ID N0:26). 
54. A method for producing a magnetic nanoparticle pro be 
composition for facilitating molecular imaging, comprising: 
combining a magnetic nanoparticle with a biocompatible 15 
coating; 
adding a targeting probe; and 
adding an intracellular delivery ligand; 
56 
wherein the intracellular delivery ligand is selected from the 
group consisting of the HSY VP22 peptide (SEQ ID N0:2), 
the ANTP peptide (SEQ ID N0:3 ), the W /R peptide (SEQ ID 
N0:4), the NLS* peptide (SEQ ID N0:5), the AlkCWKI8 
peptide (SEQ ID N0:6), the DiCWK18 peptide (SEQ ID 
N0:7), the transportan peptide (SEQ ID NO: 8), the DipaLytic 
peptide (SEQ ID N0:9), the K16RGD peptide (SEQ ID 
NO:lO), the Pl peptide (SEQ ID NO:ll ), the P2 peptide 
(SEQ ID N0:12), the P3 peptide (SEQ ID N0:13), the P3a 
peptide (SEQ ID NO: 14 ), the P9 .3 peptide (SEQ ID NO: 15), 
the Plae peptide (SEQ ID NO: 16), the Kplae peptide (SEQ ID 
NO: 17). the cKplae peptide (SEQ ID NO: 18), the MGP pep-
tide (SEQ ID NO: 19), the HA2 peptide (SEQ ID N0:20), the 
LARL46 peptide (SEQ ID N0:21), the Hel-11-7 peptide 
(SEQIDN0:22), theKKpeptide(SEQIDN0:23), theKWK 
peptide (SEQ ID N0:24), the Rf! peptide (SEQ ID N0:25), 
and the Loligomer peptide (SEQ ID N0:26). 
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